UniProt ID	Species Name	Protein Name	e-value	Similarity

Q9XKY50	Phytomonas serpens	MURF1	5.3e-148	100.0%

Q33559	Leishmania tarentolae	MURF1	2.7e-109	90.9%

Q8HE85	Trypanosoma sp.	MURF1	3.1e-17	87.6%

Q33547	Blastocrithidia culicis	MURF1	1.2e-16	86.5%

Q33552	Crithidia fasciculata	MURF1	6e-16	88.4%

Q33556	Herpetomonas muscarum	MURF1	5.1e-13	85.0%

Q34937	Leishmania. tarentolae	MURF2	2e-09	60.4%

Q34096	Crithidia fasciculata	MURF2	3.2e-09	56.3%

Q34192	Crithidia oncopelti	NAD5	3.8e-09	54.5%

P48903	Chondrus crispus	NAD2	5.4e-07	57.9%

Q5LRX2	Silicibacter pomeroyi	Putative membrane protein	1.2e-06	58.0%

Q6E773	Saprolegnia ferax	NAD2	1.5e-06	53.8%

Q6SKY5	Speleonectes tulumensis	NAD5	2.3e-06	55.2%

Q5AG49	Candida albicans	Hypothetical protein	3.3e-06	67.7%

Q5AGI5	Candida albicans	Hypothetical protein	7.1e-06	67.9%

Q8SKS6	Ancylostoma duodenale	NAD4	7.4e-06	57.3%

Q85TH7	Melipona bicolor	NAD4	7.7e-06	58.1%

Q33575	Trypanosoma brucei	NAD4	8.7e-06	57.3%

P24499	Trypanosoma brucei brucei	ATP6	1.1e-05	55.4%

Q70NW4	Strongyloides stercoralis	NAD4	1.2e-05	56.7%

Q33570	Trypanosoma cruzi	ATP6	1.5e-05	56.9%

Q5CV17	Cryptosporidium parvum	Hypothetical protein	1.5e-05	61.5%

Q057W5	Buchnera aphidicola	NADH dehydrogenase I chain L	1.9e-05	54.9%

Q8IBJ6	Plasmodium falciparum	Hypothetical protein	2.9e-05	58.4%

UniProt ID	Species Name	Protein Name	e-value	Similarity

Q5AGI5	Candida albicans	Hypothetical protein	7.1e-06	67.9%

Q8SKS6	Ancylostoma duodenale	NAD4	7.4e-06	57.3%

Q85TH7	Melipona bicolor	NAD4	7.7e-06	58.1%

Q33575	Trypanosoma brucei	NAD4	8.7e-06	57.3%

P24499	Trypanosoma brucei brucei	ATP6	1.1e-05	55.4%

Q70NW4	Strongyloides stercoralis	NAD4	1.2e-05	56.7%

Q33570	Trypanosoma cruzi	ATP6	1.5e-05	56.9%

Q5CV17	Cryptosporidium parvum	Hypothetical protein	1.5e-05	61.5%

Q057W5	Buchnera aphidicola	NADH dehydrogenase I chain L	1.9e-05	54.9%

Q8IBJ6	Plasmodium falciparum	Hypothetical protein	2.9e-05	58.4%


Algal species	Molecular technique	Bacterial phyla	Country origin	Reference

CHLOROPHYTA

Bryopsis hypnoides	CLO, FISH	BA, FI, PR (al, ep, ga)	Mexico	Hollants et al. (2011a,b)

Bryopsis pennata	CLO, FISH	BA, FI, PR (al, ep, ga)	Mexico	Hollants et al. (2011a,b)

Caulerpa taxifolia	CLO, RFLP	BA, PR (al, be, de, ga)	4 Countries	Meusnier et al. (2001)

Chara aspera	FISH	AC, BA, PL, PR (al, be, ga)	Germany	Hempel et al. (2008)

Desmidium grevillii	CLO	BA, PR (al, be, ga)	USA	Fisher et al. (1998)

Halimeda opuntia	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)

Hyalotheca dissiliens	CLO	BA, PR (al, be, ga)	USA	Fisher et al. (1998)

Spondylosium pulchrum	CLO	BA, PR (al, be, ga)	USA	Fisher et al. (1998)

Ulva australis	CLO, DGGE	AC, BA, PL, PR (al, de, ga)	Australia	Longford et al. (2007)

Ulva australis	CLO	AC, BA, CY, PL, PR (al, de, ga), VE	Australia	Burke et al. (2011b)

Ulva australis	CFISH, DGGE	BA, PR (al, ga)	Australia	Tujula et al. (2010)

Ulva intestinalis	CLO, DGGE	AC, BA, PR (al, de, ep, ga), VE	Germany	Lachnit et al. (2011)

Ulva prolifera	CLO, DGGE	AC, BA, CY, FI, FU, PL, PR (al, be, de, ep, ga), SP, VE	China	Liu et al. (2011)

HETEROKONTOPHYTA

Dictyota bartayresiana	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)

Fucus vesiculosus	CLO, DGGE	BA, CY, PL, PR (al, be, de, ep, ga), VE	Germany	Lachnit et al. (2011)

Laminaria hyperborea	DGGE, FISH	AC, BA, CY, PL, PR (al, be, ga), VE	Norway	Bengtsson et al. (2010)

Laminaria rodriguezii	CLO	AR*, PR (be)	Spain	Trias et al. (2012)

Saccharina latissima	CLO, DGGE	BA, PR (al, ga)	Germany	Staufenberger et al. (2008)

RHODOPHYTA

Coralline crustose	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)

Delisea pulchra	CLO, DGGE	AC, BA, CH, CY, PL, PR (al, de, ga), VE	Australia	Longford et al. (2007)

Delisea pulchra	CLO, DGGE	BA, PL, PR (al, ga)	Australia	Fernandes (2011)

Gracilaria vermiculophylla	CLO, DGGE	AC, CY, DT, PL, PR (al, be, de)	Germany	Lachnit et al. (2011)

Osmundaria volubilis	CLO	AR*, PR (be)	Spain	Trias et al. (2012)

Phyllophora crispa	CLO	AR*, PR (be)	Spain	Trias et al. (2012)

Porphyra yezoensis	CLO	BA, LE, PR (al, be, ga)	Japan	Namba et al. (2010)

3 spp. macroalgae	CLO, TRFLP	BA, CY, PL, PR (al, ga), VE	Chile	Hengst et al. (2010)

12 spp. macroalgae	CLO	PL	Portugal	Lage and Bondoso (2011)

Unidentified turf algae	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)

Algal species	Molecular technique	Bacterial phyla	Country origin	Reference

CHLOROPHYTA

Bryopsis hypnoides	CLO, FISH	BA, FI, PR (al, ep, ga)	Mexico	Hollants et al. (2011a,b)

Bryopsis pennat	CLO,	BA, 	Me	Hol

a	 FISH	FI, PR (al, ep, ga)	xico	lants et al. (2011a,b)

Caulerpa taxifolia	CLO, RFLP	BA, PR (al, be, de, ga)	4 Countries	Meusnier et al. (2001)

Chara aspera	FISH	AC, BA, PL, PR (al, be, ga)	Germany	Hempel et al. (2008)

Desmidium grevillii	CLO	BA, PR (al, be, ga)	USA	Fisher et al. (1998)

Halimeda opuntia	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)

Hyalotheca dissiliens	CLO	BA, PR (al, be, ga)	USA	Fisher et al. (1998)

Spondylosium pulchrum	CLO	BA, PR (al, be, ga)	USA	Fisher et al. (1998)

Ulva australis	CLO, DGGE	AC, BA, PL, PR (al, de, ga)	Australia	Longford et al. (2007)

Ulva australis	CLO	AC, BA, CY, PL, PR (al, de, ga), VE	Australia	Burke et al. (2011b)

Ulva australis	CFISH, DGGE	BA, PR (al, ga)	Australia	Tujula et al. (2010)

Ulva intestinalis	CLO, DGGE	AC, BA, PR (al, de, ep, ga), VE	Germany	Lachnit et al. (2011)

Ulva prolifera	CLO, DGGE	AC, BA, CY, FI, FU, PL, PR (al, be, de, ep, ga), SP, VE	China	Liu et al. (2011)

HETEROKONTOPHYTA

Dictyota bartayresiana	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)

Fucus vesiculosus	CLO, DGGE	BA, CY, PL, PR (al, be, de, ep, ga), VE	Germany	Lachnit et al. (2011)

Laminaria hyperborea	DGGE, FISH	AC, BA, CY, PL, PR (al, be, ga), VE	Norway	Bengtsson et al. (2010)

Laminaria rodriguezii	CLO	AR*, PR (be)	Spain	Trias et al. (2012)

Saccharina latissima	CLO, DGGE	BA, PR (al, ga)	Germany	Staufenberger et al. (2008)

RHODOPHYTA

Coralline crustose	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)

Delisea pulchra	CLO, DGGE	AC, BA, CH, CY, PL, PR (al, de, ga), VE	Australia	Longford et al. (2007)

Delisea pulchra	CLO, DGGE	BA, PL, PR (al, ga)	Australia	Fernandes (2011)

Gracilaria vermiculophylla	CLO, DGGE	AC, CY, DT, PL, PR (al, be, de)	Germany	Lachnit et al. (2011)

Osmundaria volubilis	CLO	AR*, PR (be)	Spain	Trias et al. (2012)

Phyllophora crispa	CLO	AR*, PR (be)	Spain	Trias et al. (2012)

Porphyra yezoensis	CLO	BA, LE, PR (al, be, ga)	Japan	Namba et al. (2010)

3 spp. macroalgae	CLO, TRFLP	BA, CY, PL, PR (al, ga), VE	Chile	Hengst et al. (2010)

12 spp. macroalgae	CLO	PL	Portugal	Lage and Bondoso (2011)

Unidentified turf algae	CLO	AC, BA, CH, CL, CY, FI, PL, PR	N. Antilles	Barott et al. (2011)


	Type 2 diabetes phenotype A (n = 77)

Age (years)	60 ± 11

Male (%)	65.9

BMI (kg/m2)	29.6 ± 6.2

Waist (cm)	104 ± 15

Diabetes duration (years)	12 ± 11

Insulin use (%)	58

Lipid lowering drugs (%)	30

HbA1c (%)	9.1 ± 2.1

Hypertension (%) 1	69.4

Retinopathy (%)	29.6

Albuminuria (%)	24

Coronary heart disease (%) 2	5.6

Total cholesterol (mmol/L)	4.78 ± 1.09

Triglycerides (mmol/L)	1.46 ± 0.79

VLDLc (mmol/L)	0.65 ± 0.30

LDLc (mmol/L)	2.86 ± 0.95

HDLc (mmol/L)	1.28 ± 0.33

NEFA (mmol/L)	0.64 ± 0.29

apoB (g/L)	0.93 ± 0.32

apoA-I (g/L)	1.46 ± 0.24

apoA-II (g/L)	0.33 ± 0.07

LDL size (nm)	26.0 ± 0.4


Particle	Loading capacity (%)	Loading efficiency (%)	Size (nm)	Administration route	In vitro/in vivo results	Ref.

NLCs (glyceryl tridecanoate, glyceryl tripalmitate, soy lecithin and Kolliphor HS15, and chitosan)	3	99	50	Oral	High stability in both acidic and neutral environments.In vitro studies performed in THP-1-derived macrophages showed a decrease in inflammation and accumulation of cholesterol.	[27]

NLCs (phosphatidylcholine, Kolliphor HS15, and alpha-tocopherol acetate)	10	96	108	N/A	Increased EGCG stability. Enhanced accumulation inside macrophages and decrease in the production of MCP-1.	[28]

Phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, and phosphatidylinositol	N/A	N/A	30–80	Oral	Enhanced EGCG oral bioavailability in vivo and induction of α-secretase activity in neuronal cells in vitro.	[29]

NLCs (cetyl palmitate/Phospholipon 80, sesame oil, and Tween-80)	2.7–3.6	99	126–167	Topical	Photodegradation of EGCG under UVA radiation.	[30]

SLN (glycerol monostearate, stearic acid, soya lecithin, and Pluronic F68)	N/A	67	157	N/A	Enhanced stability in physiological fluids. Increased induction of cell death in breast cancer cells MDA-MB-231 and prostate cancer cells DU-145.	[31]

Cationic lipid nanocarriers (Softisan® 100, Poloxamer 188, glycerol, Lipoid® S75, and CTAB/DDAB)	N/A	N/A	~150	Ocular	Prolonged release of EGCG in biological medium. Permeation of rabbit cornea and sclera.	[32]

Particle	Loading capacity (%)	Loading efficiency (%)	Size (nm)	Administration route	In vitro/in vivo results	Ref.

NLCs (glyceryl tridecanoate, glyceryl tripalmitate, soy lecithin and Kolliphor HS15, and chitosan)	3	99	50	Oral	High stability in both acidic and neutral environments.In vitro studies performed in THP-1-derived macrophages showed a decrease in inflammation and accumulation of cholesterol.	[27]

NLCs (phosphatidylcholine, Kolliphor HS15, and alpha-tocopherol acetate)	10	96	108	N/A	Increased EGCG stability. Enhanced accumulation inside macrophages and decrease in the production of MCP-1.	[28]

Phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, and phosphatidylinositol	N/A	N/A	30–80	Oral	Enhanced EGCG oral bioavailability in vivo and induction of α-secretase activity in neuronal cells in vitro.	[29]

NLCs (cetyl palmitate/Phospholipon 80, sesame oil, and Tween-80)	2.7–3.6	99	126–167	Topical	Photodegradation of EGCG under UVA radiation.	[30]

SLN (glycerol monostearate, stearic acid, soya lecithin, and Pluronic F68)	N/A	67	157	N/A	Enhanced stability in physiological fluids. Increased induction of cell death in breast cancer cells MDA-MB-231 and prostate cancer cells DU-145.	[31]

Cationic lipid nanoc	N/A		~	Oc	Prolonged release of EGCG in biological 	[3

Particle	Loading efficiency (%)	Size (nm)	Administration route	In vitro/in vivo results	Ref.

arriers (Softisan® 100, Poloxamer 188, glycerol, Lipoid® S75, and CTAB/DDAB)	N/A	150	ular	medium. Permeation of rabbit cornea and sclera.	2]


Model	Unstandardized Coefficients B	Unstandardized Coefficients SE	Standardized Coefficient ß	t	p

A. Results of the linear Regression for Variables Predicting PTSD Symptoms

 Constant	−3.28	1.75		−1.88	p = .063

 MACE SUM	0.21	0.06	.29	3.42	p = .001

 Physical Neglect at age 5	2.28	0.80	.24	3.86	p = .005

 Emotional Neglect at age 6	0.60	0.43	.12	1.41	p = .161

 Sexual Abuse at age 12	6.73	1.89	.25	3.56	p = .001

B. Results of the linear Regression for Variables Predicting Symptoms of Shutdown Dissociation

 Constant	3.47	0.73		−1.88	p < .001

 Physical Neglect at age 5	0.70	0.48	.14	1.46	p = .147

 Emotional Neglect at age 4	0.57	0.26	.21	2.17	p = .032

 Parental Non-verbal Emotional Abuse at age 14	0.44	0.26	.16	1.73	p = .086

 Sexual Abuse at age 12	3.02	1.12	.22	2.69	p = .008

C. Results of the linear Regression for Variables Predicting Symptoms of Depression

 Constant	14.82	1.29		11.48	p < .001

 F2 diagnosis	−5.12	0.14	−.34	−4.49	p < .001

 MACE duration	0.01	0.01	.15	1.39	p = .166

 Emotional Neglect at age 9	0.51	0.30	.17	1.67	p = .097

 Sexual Abuse at age 12	2.69	1.37	.16	1.97	p = .051

Model	Unstandardized Coefficients B	Unstandardized Coefficients SE	Standardized Coefficient ß	t	p

MACE SUM	0.21	0.06	.29	3.42	p = .001

Physical Neglect at age 5	2.28	0.80	.24	3.86	p = .005

Emotional Neglect at age 6	0.60	0.43	.12	1.41	p = .161

Sexual Abuse at age 12	6.73	1.89	.25	3.56	p = .001

B. Results of the linear Regression for Variables Predicting Symptoms of Shutdown Dissociation

Constant	3.47	0.73		−1.88	p < .001

Physical Neglect at age 5	0.70	0.48	.14	1.46	p = .147

Emotional Neglect at age 4	0.57	0.26	.21	2.17	p = .032

Parental Non-verbal Emotional Abuse at age 14	0.44	0.26	.16	1.73	p = .086

Sexual Abuse at age 12	3.02	1.12	.22	2.69	p = .008

C. Results of the linear Regression for Variables Predicting Symptoms of Depression

Constant	14.82	1.29		11.48	p < .001

F2 diagnosis	−5.12	0.14	−.34	−4.49	p < .001

MACE duration	0.01	0.01	.15	1.39	p = .166

Emotional Neglect at age 9	0.51	0.30	.17	1.67	p = .097

Sexual Abuse at age 12	2.69	1.37	.16	1.97	p = .051


Characteristic	Rotavirus Diarrhea (n = 71)	Nonrotavirus Diarrhea (n = 149)	P Value

Age, moa	9 (3–27)	10 (2–30)	.335

Male sex	42 (59.2)	78 (52.3)	.422

Prior hospital admission for diarrhea	22 (31.0)	37 (24.8)	.423

Home has a separate room for kitchen	40 (56.3)	88 (59.1)	.813

No. of bedrooms in homea	2 (1–4)	2 (1–4)	.278

No. of people sleeping in homea	7 (1–20)	6 (4–21)	.368

No. of children sleeping in homea	4 (1–8)	3 (1–13)	.459

Family owns a mattress	51 (71.8)	98 (65.8)	.457

Family owns a mobile phone	70 (98.6)	130 (87.2)	.013

Family owns a radio	38 (53.5)	79 (53.0)	1.000

From the Iraqw tribe	37 (52.1)	95 (63.8)	.133

Maternal agea	27 (16–47)	26 (17–41)	.919

Mother completed secondary school	50 (70.4)	87 (58.4)	.116

Protected drinking water source	27 (38.0)	70 (47.0)	.269

Child still breastfeeding	63 (88.7)	119 (79.9)	.151


Author	Age	Symptoms	Site of tumor	Histology	Treatment	Relapse(months)	Treatment of relapse

Our case	56	Urinary symptomsLower abdominal distention	Corpus	IT	Hysterectomy	Yes (3)	BEP × 1

Newsom-Davis et al., 2009 [5]	82	Vaginal bleeding	Corpus	IT	Hysterectomy and bilateral salpingooophorectomy	Yes (6)	EP × 1, ET × 1, TP × 1 + surgery

Gomez-Lobo et al., 2007 [6]	15	Vaginal bleedingPelvic pain	ns	IT, high grade	Lesion excision + chemotherapy	ns	—

Iwanaga et al., 1993 [7]	36	Pelvic painLower abdominal distention	Fundus	IT, grade 3	Hysterectomy + chemotherapy (VAC × 2)	No	—

Ansah-Boateng et al., 1985 [8]	37	Vaginal bleeding	ns	IT, grade 2	Hysterectomy + radiotherapy	No	—

Author	Age	Symptoms	Site of tumor	Histology	Treatment	Relapse(months)	Treatment of relapse

Our case	56	Urinary symptomsLower abdominal distention	Corpus	IT	Hysterectomy	Yes (3)	BEP × 1

Newsom-Davis et al., 2		Vaginal 	Corpus		Hysterectomy and bilateral sal	Ye	EP × 1, E

Author	Age	Symptoms	Site of tumor	Histology	Treatment	Relapse(months)	Treatment of relapse

009 [5]	82	bleeding		IT	pingooophorectomy	s (6)	T × 1, TP × 1 + surgery

Gomez-Lobo et al., 2007 [6]	15	Vaginal bleedingPelvic pain	ns	IT, high grade	Lesion excision + chemotherapy	ns	—

Iwanaga et al., 1993 [7]	36	Pelvic painLower abdominal distention	Fundus	IT, grade 3	Hysterectomy + chemotherapy (VAC × 2)	No	—

Ansah-Boateng et al., 1985 [8]	37	Vaginal bleeding	ns	IT, grade 2	Hysterectomy + radiotherapy	No	—


n		1108

Age (yrs)	Median	61.5

	Range	40.2-79

PSA (ng/ml)	Median	6.99

	Range	0.3-20

Pathological Stage	pT2	770 (69.6%)

	pT3	335 (30.4%)

Tumour Grade	Low (GS 6)	153 (13.8%)

	Intermediate (GS 7)	848 (76.5%)

	GS 3+4	583 (68.8%)

	GS 4+3	265 (31.3%)

	High (GS 8-10)	107 (9.7%)

Extraprostatic Extension	Absent	782 (70.6%)

	Present	326 (29.4%)

Seminal Vesicle Invasion	Absent	1042 (94.1%)

	Present	66 (6%)

Recurrence	No	812 (76.8%)

(n=1057)	Yes	245 (23.2%)

Total Tumour Volume (cc)	Median	2.6

	IQR	1.3-4.8

Prostate Volume (cc)	Median	32.2

	IQR	24.2-43.5


Parameter	Unit	Tier within the breeding program

Nucleus	Multiplier	Commercial

Flock breeding ewes	Head	826	7000	180,000

Flock breeding rams	Head	10	70	1800

Ewes mated to terminal sires	%	0	0	20

Ewes/ram	Head	80	100	100

Ewe replacement rate	%	35	35	30

Mixed age ewe lambing ratea	%	210	190	165

Ewe lamb lambing rate	%	100	90	80

Lamb survival	%	79	79	82

Weaning rate	%	166	150	135

Lambs sold as storesb	%	–	–	20

Parameter	Unit	Tier within the breeding program

Nucleus	Multiplier	Commercial

Flock breeding ewes	Head	826	7000	180,000

Flock breeding rams	Head	10	70	1800

Ewes mated to terminal sires	%	0	0	20

Ewes/ram	Head	80	100	100

Ewe replacement rate	%	35	35	30

Mix				16

Parameter	Unit	Tier within the breeding program

Nucleus	Multiplier	Commercial

ed age ewe lambing ratea	%	210	190	5

Ewe lamb lambing rate	%	100	90	80

Lamb survival	%	79	79	82

Weaning rate	%	166	150	135

Lambs sold as storesb	%	–	–	20


				Cluster

		Professional	Consumer	Organizational	Financial	Regulatory

	Breast	4	9	4	0	0

	Gastrointestinal	2	2	2	0	0

	Genitourinary	2	4	2	0	0

	Gynecological	1	1	1	0	0

	Head and neck	0	2	0	0	0

Diagnosis	Hematologic	1	2	1	0	0

	Lung	0	3	0	0	0

	Melanoma	1	1	1	0	0

	Neuro-oncology	0	0	0	0	0

	Sarcoma	1	0	1	0	0

	Not specified	5	6	5	0	0

			Cluster

	Professional	Consumer	Organizational	Financial	Regulatory

Lung	0	3	0	0	0

Melanoma	1	1	1	0	0

Neuro-oncology	0	0	0	0	0

Sarcoma	1	0	1	0	0

Not specified	5	6	5	0	0


	Laparoscopic cholecystectomy(n = 120)	Small-incision cholecystectomy(n = 137)	Statistical analysis

Mortality	0	0

Complications	21	16	p = 0.119

intra-operative	5	3	p = 0.363

postoperative	16	13	p = 0.331

Failed symptom relief	11 (9.2%)	14 (10.2%)	p = 0.777

Operative time (min):

mean (SD)	71.9 (25.8)	60.4 (18.3)	p < 0.001

median (range)	68.5 (26-215)	60.0 (29-105)

Conversion rate	14 (11.7%)	22 (16.1%)	p = 0.312

Operative team:

surgeon-resident	15 (12.5%)	21 (15.3%)	p = 0.515

resident-surgeon	84 (70.0%)	100 (73.0%)	p = 0.596

resident-resident	21 (17.5%)	18 (13.1%)	p = 0.331

Hospital stay*

mean (SD)	2.4 (4.6)	3.1 (12.4)	p = 0.560

median (range)	1 (1 - 36)	2 (1 - 144)

Hospital stay* (without 1 extreme value)mean (SD)	2.1 (3.4)	2.0 (2.4)	p = 0.877

Number of patients with:

1 night stay postoperative	67 (55.8%)	62 (45.3%)	p = 0.091

2 nights stay postoperative	38 (31.7%	56 (40.9%)	p = 0.127

	Laparoscopic cholecystectomy(n = 120)	Small-incision cholecystectomy(n = 137)	Statistical analysis

Failed symptom relief	11 (9.2%)	14 (10.2%)	p = 0.777

Operative time (min):

mean (SD)	71.9 (25.8)	60.4 (18.3)	p < 0.001

median (range)	68.5 (26-215)	60.0 (29-105)

Conversion rate	14 (11.7%)	22 (16.1%)	p = 0.312

Operative team:

surgeon-resident	15 (12.5%)	21 (15.3%)	p = 0.515

resident-surgeon	84 (70.0%)	100 (73.0%)	p = 0.596

resident-resident	21 (17.5%)	18 (13.1%)	p = 0.331

Hospital stay*

mean (SD)	2.4 (4.6)	3.1 (12.4)	p = 0.560

median (range)	1 (1 - 36)	2 (1 - 144)

Hospital stay* (without 1 extreme value)mean (SD)	2.1 (3.4)	2.0 (2.4)	p = 0.877

Number of patients with:

1 night stay postoperative	67 (55.8%)	62 (45.3%)	p = 0.091

2 nights stay postoperative	38 (31.7%	56 (40.9%)	p = 0.127


Category from the VIM tool	Phase 1	Phase 3

112 patients	16 patients

Management—investigations, e.g. fields test	88% (99)	100% (16)

Self-management—importance of taking eyedrops	83% (93)	100% (16)

Management—regular monitoring	63% (70)	81% (13)

Management—appointment issues	63% (70)	94% (15)

Treatment—options for eyedrops	60% (67)	100% (16)

Risk—family	55% (62)	100% (16)

Diagnosis	54% (60)	100% (16)

Treatment—side effects	43% (48)	100% (16)

Prognosis—loss of sight	24% (27)	100% (16)

Driving	16% (18)	94% (15)

Support—help with eyedrops	13% (15)	100% (16)

Prognosis—symptomless	11% (12)	100% (16)

Prognosis—sight can’t be recovered	10% (11)	100% (16)

Support—support groups	10% (11)	94% (15)

Prognosis—when treated most don’t go blind	3% (3)	100% (16)

Registration of loss of sight	2% (2)	6% (1)

Category from the VIM tool	Phase 1	Phase 3

112 patients	16 patients

Support—support groups	10% (11)	94% (15)

Prognosis—when treated most don’t go blind	3% (3)	100% (16)

Registration of loss of sight	2% (2)	6% (1)


Variables	Coefficient	Standard error	p-value

Course year	- 0.542	0.215	0.015

Participation in emergency course	- 0.903	0.437	0.044

bles	fficient	dard error	value

Course year	- 0.542	0.215	0.015

Participation in emergency course	- 0.903	0.437	0.044


Complication	Frequencyn	Percent%

Present	73	44.8

Absent	90	55.2

Total	163	100.0

Complication	Frequencyn	Percent%

Present	73	44.8

Absent	90	55.2

Tota		100.

Complication	Frequencyn	Percent%

l	163	0


Warm-up 1.47 min	Front leaning stance	L stance

Begin with Postural alignment.Shoulders relaxed and in alignment with hips and feet and all facing forward. When standing, feet start shoulder width apart. Repeat each 4 times.	Step forward one stride length, toes first and facing forward as knee bends. Maintain feet shoulders width apart. Opposite foot, toes slightly turned out (30°) and leg straight. Shift weight to back foot. Bend back knee and straighten front knee when shifting weight to back foot. Both feet remain flat on floor at all times. Connect breath and arms with leg movements (as weight shifts forward, raise arms and take in a deep breath, as shifting back, exhale).	Step back with one foot, making an L with feet (creating a 90° angle). Feet should be a comfortable distance apart and the heel of the back foot should land in line with front foot. Shift weight to back foot and front foot should be settled on heel with toes pointing up in the air. Most of weight on the back foot with knee bent and front knee is straight. Shift weight from back to front foot and bend front knee as back knee straightens. Connect breath and arms with leg movements (as weight shifts forward, raise arms and take in a deep breath, as shifting back, exhale).

Sign Gestures 8.13 min	Description	Integration of Breath

Healthy, Happy, Holy Practiced from standing position, incorporating the front leaning stance	Healthy: Bring hands to chest with palms open. Extend arms forward in a powerful manner with hands clenched into fist as muscles in forearm and upper arm tighten, assuming the boxers posture. Follow timing of music.	Breath:Breathe in as hands placed on chest. Breathe out as arms extended.

Happy: Rolling your hands upward and outward, starting low in your abdomen. This rolling motion is continuous.	Breath: Breathe in as hands move in a continuous motion rolling outward. Breathe out with continuous motion.

Holy: The right index and middle finger (the H sign) glide across the palm of your left hand extending upward and out on an angle.	Breath: Breathe in as the right fingers are placed on the palm of left hand. Breathe out as fingers brush across palm and extend upward and outward.

Check blood pressure and heart rate at 0, 5, and 10 min. (Record heart rate every minute, and up to 10 min following cessation of movement.)

Warm-up 1.47 min	Front leaning stance	L stance

Check blood pressure and heart rate at 0, 5, and 10 min. (Record heart rate every minute, and up to 10 min following cessation of movement.)


Groups	Treatment groups	Description

Group I	Normal control	Received only diet and water

Group II	Vehicle control	Received water and treated with SRBC

Group III	Positive control	Received Ginseng extract 200 mg/kg

Group IV	Low dosage treatment	Received 125 mg/kg of D. morbifera

Group V	Intermediate dosage treatment	Received 250 mg/kg of D. morbifera

Group VI	High dosage treatment	Received 500 mg/kg of D. morbifera

Groups	Treatment groups	Description

Group VI	High dosage treatment	Received 500 mg/kg of D. morbifera


Branch	Leading toa	#Sets	#Genes in Sets	# Significant Sets

Before Pruning	Without Top Scoring Gene	After Pruning

1	Homininae	African Apes(Hu, Ch, Go)	1,415	7,600	8	6	2

2	Hominidae	Great Apes(Hu, Ch, Go, Or)	1,424	7,849	34	32	7

3	Hominoidae	Apes(Hu, Ch, Go, Gi)	1,441	8,016	43	42	6

4	Catarrhini	Apes & Old World Monkeys (Hu, Ch, Go, Gi, Ma)	1,441	8,058	95	93	9

Branch	Leading toa	#Sets	#Genes in Sets	# Significant Sets

Before Pruning	Without Top Scoring Gene	After Pruning

	Hominin	Afr	1,415	7,60		6	2

1	ae	ican Apes(Hu, Ch, Go)		0	8

2	Hominidae	Great Apes(Hu, Ch, Go, Or)	1,424	7,849	34	32	7

3	Hominoidae	Apes(Hu, Ch, Go, Gi)	1,441	8,016	43	42	6

4	Catarrhini	Apes & Old World Monkeys (Hu, Ch, Go, Gi, Ma)	1,441	8,058	95	93	9


Gene ID	Annotation	FPKM Ctrl	FPKM -N	Log2 FC

GRMZM2G326707	Inorganic phosphate transmembrane transporter, PHT1;4	73.0	305.5	2.07

GRMZM2G154090	Inorganic phosphate transmembrane transporter, PHT1;4	6.7	695.6	6.69

GRMZM2G112377	Inorganic phosphate transmembrane transporter, PHT1;4	1.4	271.3	7.64

GRMZM2G069542	Phosphoenolpyruvate carboxylase	92.7	154.5	0.74

GRMZM2G074122	Phosphoenolpyruvate carboxylase	42.7	73.6	0.79

GRMZM2G110714	Phosphoenolpyruvate carboxylase	3.2	22.9	2.83

GRMZM2G008507	Sucrose-phosphate synthase	1.2	77.9	6.02

GRMZM2G047995	Lipase class 3 family protein	4.0	87.0	4.45

GRMZM2G169562	Lipase class 3 family protein	2.9	27.3	3.23

GRMZM5G829946	Senescence-related gene 3, glycerophosphodiester phosphodiesterase	0.3	159.3	8.92

GRMZM2G064962	Glycerophosphoryl diester phosphodiester family protein	19.2	108.0	2.49

GRMZM2G315848	Protein nucleotide pyrophosphatase/phosphodiesterase	6.7	65.8	3.29

GRMZM2G477503	Sulfoquinovosyldiacylglycerol 2	6.5	348.0	5.75

GRMZM2G141320	1,2-diacylglycerol 3-beta-galactosyltransferase/UDP-galactosyltransferase	0	159.8	–

GRMZM2G152447	Acid phosphatase/protein serine/threonine phosphatase	1.0	318.8	8.34

GRMZM2G138756	Acid phosphatase/protein serine/threonine phosphatase	0.1	17.7	8.00

GRMZM5G836174	Phosphatase	0.5	1991.8	11.83

GRMZM2G015908	Phosphatase	3.9	309.9	6.30

GRMZM2G021106	Phosphatase	0.4	48.1	6.81

GRMZM2G171423	SPX domain gene 2	1.0	84.6	6.46

GRMZM5G805389	SPX domain gene 3	3.3	1246.0	8.57

GRMZM2G065989	SPX domain gene 3	2.5	1008.0	8.65

GRMZM5G828488	SPX domain gene 3	0.5	399.5	9.65


	Metformin	Pioglitazone	Empagliflozin	Anticipated effect?

Cardiovascular death	↓	↔	↓↓	↓↓↓

All-cause death	↓	↔	↓↓	↓↓↓

Myocardial infarction	↓	↓	↔	↓↓

Stroke	↓	↓	↔	↓↓

Peripheral arterial disease	↓	↔	↔	↓

Fluid retention	↔	↑	↓	↔

Heart failure	↔	↑	↓	↔

Weight	↓	↑	↓	↓

Blood pressure	↔	↓	↓	↓↓

HbA1c	↓	↓	↓	↓↓↓

LDL-cholesterol	↓	↔	↑	↔

HDL-cholesterol	↔	↑	↑	↑↑

Albuminuria	↔	↓	↓	↓↓

Insulin sensitivity	↑	↑↑	↑	↑↑↑↑

	Metformin	Pioglitazone	Empagliflozin	Anticipated effect?

Peripheral arterial disease	↓	↔	↔	↓

Fluid retention	↔	↑	↓	↔

Heart failure	↔	↑	↓	↔

Weight	↓	↑	↓	↓

Blood pressure	↔	↓	↓	↓↓

HbA1c	↓	↓	↓	↓↓↓

LDL-cholesterol	↓	↔	↑	↔

HDL-cholesterol	↔	↑	↑	↑↑

Albuminuria	↔	↓	↓	↓↓

Insulin sensitivity	↑	↑↑	↑	↑↑↑↑


Year	Confirmed positive	Donor population	Prevalence by gender	Total prevalence

1st year	Male	124	80253	0.15%	0.18%

Female	36	6524	0.55%

2nd year	Male	133	81841	0.16%	0.19%

Female	34	6044	0.56%

Total		327	174662		0.18%

Year	Confirmed positive	Donor population	Prevalence by gender	Total prevalence

1st year	Female	36	6524	0.55%	0.18%

2nd year	Male	133	81841	0.16%	0.19%

Female	34	6044	0.56%

Total		327	174662		0.18%


Variable	Subgroups	Number of respondents	Percentages

Age (years)	<20	33	11.3

20–25	221	75.4

>25	39	13.3

Age of menarche	<13	83	28.3

13–15	161	54.0

> 15	49	16.7

Gynecological age (years)	< 5	14	4.8

5–10	214	73.0

> 10	65	22.2

Religious affiliationa	Christianity	208	71.0

Islam	79	27.0

Type of accommodation at menarchea	Single room	46	15.7

Chamber and hall	55	18.8

Several rooms in a compound house	52	17.7

Self-contained apartment	126	43.0

Mansion	10	3.4

Area of residence during vacationa	Urban area	181	61.8

Sub-urban	88	30.0

Rural	21	7.2

Variable	Subgroups	Number of respondents	Percentages

Age (years)	<20	33	11.3

20–25	221	75.4

>25	39	13.3

Age of menarche	<13	83	28.3

13–15	161	54.0

> 15	49	16.7

Gynecological age (	<

years)	5	14	4.8

5–10	214	73.0

> 10	65	22.2

Religious affiliationa	Christianity	208	71.0

Islam	79	27.0

Type of accommodation at menarchea	Single room	46	15.7

Chamber and hall	55	18.8

Several rooms in a compound house	52	17.7

Self-contained apartment	126	43.0

Mansion	10	3.4

Area of residence during vacationa	Urban area	181	61.8

Sub-urban	88	30.0

Rural	21	7.2


	Dyad 1	Dyad 2	Dyad 3	Dyad 4	Dyad 5

Mother age	43	31	52	45	48

Youth age	13	13	13	13	13

Youth grade	8	8	8	8	8

Youth gender	Girl	Girl	Girl	Boy	Boy

Mother income	$40–49K	$10–19K	$50–74K	$75–99K	$50–74K

Mother education level	Some college	Some college	College graduate	College graduate	College graduate

Race	White	African American	White	White	White


	Number of responses	%	Overall(N Trusts with at least one response/Total N Trusts in regionb)	Diabetes(N Trusts with at least one response)	Cardiac(N Trusts at least one response)

ENGLAND

London	27	15.2	15/22	13	13

South West	23	12.9	12/16	10	8

South Central	10	5.6	5/9	5	4

South East Coast	8	4.5	6/11	6	2

East England	16	9.0	11/17	9	5

Yorkshire & Humber	15	8.4	9/13	8	8

West Midlands	21	11.8	13/15	10	13

East Midlands	8	4.5	5/8	3	5

North East	16	9.0	6/8	4	6

North West	17	9.6	10/20	8	8

Total number in England	161	90.5	92/139	76	72

SCOTLAND	12	6.7	12 responses covering ≥7/14 health boards (2 responses only identified as “Scotland”)	6	6

WALES	3	1.7	3 responses covering 3 of the 7 local health boards.	2	3

NORTHERN IRELAND	2	1.1	2 responses covering 2 of the 5 health and social care Trusts	2	2

Total	178a	100.0


Primer name	Sequence

Notch-1

 Forward	CACTGTGGGCGGGTCC

 Reverse	GTTGTATTGGTTCGGCACCAT

Hes1

 Forward	AGCCAACTGAAAACACCTGATT

 Reverse	GGAGTTTATGATTAGCAGTGG

Dll4

 Forward	GGTGACCTGGCGAACAGACGAGCAAAAT

 Reverse	GGTGACCTGGCGAACAGACGAGCAAAAT

GAPDH

 Forward	GGCATCCTGGGCTACACT

 Reverse	CCACCACCCTGTTGCTGT

Primer name	Sequence

GAPDH

Forward	GGCATCCTGGGCTACACT

Reverse	CCACCACCCTGTTGCTGT


Features used	Attribute type

Gene Neighborhood score, obtained from STRING	Real valued, ranges from 0-999

Gene Fusion score, obtained from STRING	Real valued, ranges from 0-999

Gene Co-occurrence score, obtained from STRING	Real valued, ranges from 0-999

Gene Co-expression score, obtained from STRING	Real valued, ranges from 0-999

GO Cellular component based feature	Real valued, ranges from 0-0.5

GO: Molecular function	Real valued, ranges from 0-0.5

GO: Biological process	Real valued, ranges from 0-0.5

d	 type

Gene Neighborhood score, obtained from STRING	Real valued, ranges from 0-999

Gene Fusion score, obtained from STRING	Real valued, ranges from 0-999

Gene Co-occurrence score, obtained from STRING	Real valued, ranges from 0-999

Gene Co-expression score, obtained from STRING	Real valued, ranges from 0-999

GO Cellular component based feature	Real valued, ranges from 0-0.5

GO: Molecular function	Real valued, ranges from 0-0.5

GO: Biological process	Real valued, ranges from 0-0.5


	Number of cases	Gender (%)	Age median (Range)	PDAC stage (%)

Cohort 1 (Exploratory phase)

Healthy	n = 16	M (62.5)F (37.5)	59 (54–65)	Stage IA (16)Stage IIA (24)Stage IIB (56)ND (4)

PDAC	n = 25	M (40)F (60)	50 (47–82)

Cohort 2 (Confirmatory phase)

Healthy	n = 131	M (49.6)F (50.4)	55 (44–66)	Stage IA (1.5)Stage IB (0.8)Stage IIA (16.8)Stage IIB (66.4)Stage III (0.8)Stage IV (2.3)ND (11.4)

Chronic pancreatitis	n = 30	M (73.3)F (26.7)	53 (34–79)

PDAC	n = 131	M (49.6)F (50.4)	70 (38–88)

	Number of cases	Gender (%)	Age median (Range)

Cohort 1 (Exploratory phase)

Healthy	n = 16	M (62.5)F (37.5)	59 (54–65)

PDAC	n = 25	M (40)F (60)	50 (47–82)

Cohort 2 (Confirmatory phase)

Healthy	n = 131	M (49.6)F (50.4)	55 (44–66)

Chronic pancreatitis	n = 30	M (73.3)F (26.7)	53 (34–79)

PDAC	n = 131	M (49.6)F (50.4)	70 (38–88)

PDAC stage (%)

Cohort 1 (Exploratory phase)

Stage IA (16)Stage IIA (24)Stage IIB (56)ND (4)

Cohort 2 (Confirmatory phase)

Stage IA (1.5)Stage IB (0.8)Stage IIA (16.8)Stage IIB (66.4)Stage III (0.8)Stage IV (2.3)ND (11.4)


Haplotypes	n (%)	Number of mutated positions	95% CI


Characteristics	Cases (n = 394)	Controls (n = 794)	p valuea

Marital status (%)

Unitedb	304 (77.2%)	636 (80.1%)	0.24

Not united	90 (22.8%)	158 (19.9%)


Type of vaginal infections	Asymptomatic women (N = 261)	Symptomatic women (N = 148)	P-value	Pregnant women (N = 214)	Non-pregnant women (N = 195)	P-value	Total

Candidiasis	24 (9.2)	10 (6.8)	0.08	20 (9.3)	14 (7.2)	0.48	34 (8.2)

Bacterial vaginosis	6 (2.3)	6(4.1)	0.73	1 (0.5)	11 (5.6)	0.002	12 (2.9)


Run no.	Pretreatment conditions	H2O addition method	Solid residue (wt%)	Glucose yield (%)	Xylose yield (%)

1	105°C 6 h	Aliquot	34.9	20.7 ± 0.4	99.8 ± 2.6


Variables	Evaluation instruments	Quality of instruments	Time application instruments

Demographic & obstetric data	Included in antenatal interview	 	Antenatal

Antenatal risk of PPD	Interview (Riguetti-Veltema & et. al, [14])	Sensitivity = 84,5%, Specificity = 73%	Antenatal

Symptoms of depression	EPDS*Edinburgh Postnatal Depression Scale (Cox & et. al, [51])	Sensitivity = 86%, Specificity = 78%	Antenatal and postnatal

Relationship with partner	DASS*Dyadic Adjustement Scale (Spanier, [52])	Fidelity: Cronbach Alpha = 0.96	Antenatal and postnatal

Social support	FSSQ*Functional Social Support Questionnaire (Broadhead, [53])	Fidelity: Cronbach Alpha = 0.90	Antenatal and postnatal

Stress	Stress events* (Holmes & Rahe, [54])	 	Antenatal and postnatal

Birth outcomes	Hospital clinical data and post-partum questionnaire*	 	Postnatal

Variables	Evaluation instruments	Quality of instruments	Time application instruments

Symptoms of depression	EPDS*Edinburgh Postnatal Depression Scale (Cox & et. al, [51])	Sensitivity = 86%, Specificity = 78%	Antenatal and postnatal

Relationship with partner	DASS*Dyadic Adjustement Scale (Spanier, [52])	Fidelity: Cronbach Alpha = 0.96	Antenatal and postnatal

Social support	FSSQ*Functional Social Support Questionnaire (Broadhead, [53])	Fidelity: Cronbach Alpha = 0.90	Antenatal and postnatal

Stress	Stress events* (Holmes & Rahe, [54])		Antenatal and postnatal

Birth outcomes	Hospital clinical data and post-partum questionnaire*		Postnatal


Characteristic	Frequency	Percentage

Sex

 Male	372	62.0

 Female	228	38.0

Age category

 1 (15–35)	287	47.8

 2 (36–55)	202	33.7

 3 (≥56)	111	18.5

HIV status

 Positive	162	27.0

 Negative	438	73.0

Mycobacterial testing results

 ZN smear positive	34	12.1

 LED-FM smear positive	16	5.0

 Xpert positive	82	13.7

 Culture (MGIT and/or LJ) positive	96	16.0


BSI scale	UK outpatient mean/SD	Pretreatment score	Posttreatment score

PAR	M = 1.54/SD = 1.08∗	2.20	1.50

ANX	M = 1.87/SD = 1.03∗	2.50	1.60


Title	No of species	Authors	Reference

Sporadic study in India	20	Gosh A K, Maiti P K	[44]

Bhil of Rajasthan	17	Sharma S K	[43]

Bhil, Gamit, Kokna etc. of Maharastra	15	Patil S H	[42]

Chhattisgarh	10	Oudhia P	[41]

Chhattisgarh	7	Oudhia P	[40]

Kachch (Gujrat)	34	Gupta Leena et al.	[39]

Irular, Kurimba of Tamilnadu	26	Solvan A et al.	[38]

Kanikar, Paliyar of Taminadu	11	Ranjit Singh ASA	[37]

Mogya, Meena, Bawaria of Rajasthan	15	Mahawar, Jaroli	[33]

Saharia of Rajasthan	15	Mahawar, Jaroli	[36]

Monpas	11	Solanki GS and Chutia P	[11]

Mizoram	56	Lalramnghinglova	[12]

Chakhesang of Nagaland	23	Kakati and Doulo	[16]

Naga tribe of Nagaland	26	Jamir N S et al.	[14]

Dibrugarh (Assam)	4	Dilip Kalita	[15]

Ao tribe of Nagaland	25	Kakati L N et al.	[17]

Nyishi & Galo Tribe of Arunachal Pradesh	36	Chakravorty et al.	[13]

Biate Tribe, Dima Hasao, Assam	34	Present Study


Material	Total thermal conductivity (W/m-K)	LA (%)	TA (%)	ZA (%)	Optical (%)

Black phosphorene (zigzag)	110	32	22	31	15

Black phosphorene (armchair)	36	28	33	12	27

Blue phosphorene	78	26	27	44	3

MoS229	108	28	24	39	9

Graphene30	3600	8	15	76	1

Material	Total thermal conductivity (W/m-K)	LA (%)	TA (%)	ZA (%)	Optical (%)

Black phosphorene (armchair)	36	28	33	12	27

Blue phosphorene	78	26	27	44	3

MoS229	108	28	24	39	9

Graphene30	3600	8	15	76	1


Parameters	NGT	Pre-diabetes	p value

	(n = 24)	(n = 26)

Anthropometric measures

Age (years)	36 ± 2	39 ± 2	0.232

Weight (Kg)	69 ± 2	77 ± 3*	0.026

Body Mass Index (kg/m2)	24.0 ± 0.6	26.5 ± 0.6*	0.005

Waist Circumference (cm)	90.3 ± 1.7	98.3 ± 3.1*	0.032

Waist - Hip Ratio	0.96 ± 0.01	0.98 ± 0.01	0.070

Systolic Blood Pressure (mmHg)	119.0 ± 1.8	122.8 ± 2.6	0.240

Diastolic Blood Pressure (mmHg)	76.3 ± 1.6	76.6 ± 1.9	0.992

Biochemical parameters

OGTT

Fasting plasma glucose (mmol/l)	5.0 ± 0.1	5.7 ± 0.1**	0.0001

2Hr Post plasma glucose (mmol/l)	5.6 ± 0.2	8.1 ± 0.3**	0.0001

Glycated Hemoglobin [HbA1c] (%)	5.4 ± 0.1	5.8 ± 0.1*	0.0013

Fasting Insulin (pmol/l)	49.8 ± 5	95.1 ± 10**	0.0002

2Hr post Insulin (pmol/l)	325.8 ± 49	780.0 ± 75**	0.0001

HOMA-IR	1.9 ± 0.2	4.0 ± 0.4**	0.0001

Lipid profile

Total Cholesterol (mmol/l)	4.6 ± 0.2	4.9 ± 0.2	0.376

Serum Triglycerides (mmol/l)	1.51 ± 0.2	1.9 ± 0.2	0.166

HDL Cholesterol (mmol/l)	1.0 ± 0.04	0.9 ± 0.04	0.459

LDL Cholesterol (mmol/l)	2.9 ± 0.1	3.0 ± 0.2	0.632

VLDL Cholesterol (mmol/l)	0.7 ± 0.1	0.9 ± 0.1	0.163

Others

Serum Creatinine (μmol/l)	79.6 ± 1.8	106.9 ± 27.1	0.364

Hs-CRP (mg/l)	2.5 ± 0.5	3.1 ± 0.5	0.341

Microalbuminuria (μg/mg)	5.2 ± 0.8	7.6 ± 1.5	0.344


	Case 1	Case 2	Case 3

Age, years	59	41	46

Sex	Female	Female	Female

Initial stage	1A	ND	2A

Histology	IDC	IDC	ILC

Histological grade	2	2	1

Nuclear grade	1	2	1

Estrogen receptor (AS)	Negative (0)	Positive (8)	Positive (8)

Progesterone receptor (AS)	Negative (0)	Positive (8)	Positive (8)

HER2 status (IHC score)	Negative (0)	Negative (0)	Negative (1+)

PIK3CA hotspot mutation	H1047R	Negative	H1047R

TERT hotspot mutation	C250T	C228T	C228T

Relapse-free survival, months	83	226	270

Overall survival, months	100	446	300

Status	Alive	Alive	Alive


Code	Value	% Age	Description

J	165	2.51	Translation, ribosomal structure and biogenesis

A	0	0.00	RNA processing and modification

K	131	1.99	Transcription

L	620	9.44	Replication, recombination and repair

B	1	0.02	Chromatin structure and dynamics

D	47	0.72	Cell cycle control, Cell division, chromosome partitioning

V	67	1.02	Defense mechanisms

T	138	2.10	Signal transduction mechanisms

M	203	3.09	Cell wall/membrane biogenesis

N	30	0.46	Cell motility

U	52	0.79	Intracellular trafficking and secretion

O	152	2.31	Posttranslational modification, protein turnover, chaperones

C	185	2.82	Energy production and conversion

G	131	1.99	Carbohydrate transport and metabolism

E	215	3.27	Amino acid transport and metabolism

F	62	0.94	Nucleotide transport and metabolism

H	146	2.22	Coenzyme transport and metabolism

I	65	0.99	Lipid transport and metabolism

P	188	2.86	Inorganic ion transport and metabolism

Q	126	1.92	Secondary metabolites biosynthesis, transport and catabolism

R	535	8.14	General function prediction only

S	483	7.35	Function unknown

-	2,826	43.02	Not in COGs


Variable	EVAM (n = 85)	OVAM (n = 439)	P value

Demographics

Age (years, mean ± SD)	5.6 ± 3.0	5.3 ± 3.1	NS


	Type of ringworm

Dermatophytes	Tinea capitisn (%)	Tinea pedisn (%)	Tinea corporisn (%)	Totaln (%)

E. floccosum	0 (0.0)	1 (9.1)	0 (0.0)	1 (2.4)


SSRs	Probes used in study	References

		Mitotic chromosomes	Polytene chromosomes

A	A20		(21, 40)

C	C20		(40)

AC; AG	(AC)10; (AG)10	(27)	(27, 40)

AAC; AAG; AAT, AAC; AGC; ACT; AGC; AGG; ATC; CCG	(AAC)5; (AAG)5; (AAT)5; (ACC)5; (ACG)5; (ACT)5; (AGC)5; (AGG)5; (ATC)5; (CCG)5

GACA	(GACA)5		(21)

GATA	(GATA)5	(31)	(21)

AAGAC; AAGAG; AATAC; AATAT	(AAGAC)3; (AAGAG)3; (AATAC)3; (AATAT)3	(10)

AACAC	(AACAC)3;	(11)	(11)

SSRs	Probes used in study	References

		Mitotic chromosomes	Polytene chromosomes

AC; AG	(AC)10; (AG)10	(27)	(27, 40)

AAC; AAG; AAT, AAC; AGC; ACT; AGC; AGG; ATC; CCG	(AAC)5; (AAG)5; (AAT)5; (ACC)5; (ACG)5; (ACT)5; (AGC)5; (AGG)5; (ATC)5; (CCG)5

GACA	(GACA)5		(21)

GATA	(GATA)5	(31)	(21)

AAGAC; AAGAG; AATAC; AATAT	(AAGAC)3; (AAGAG)3; (AATAC)3; (AATAT)3	(10)

AACAC	(AACAC)3;	(11)	(11)


		N = 14 (%)

Clinical characteristics

Age (SAH), years (mean, SD)		46.1 ± 12Range: 20–63

Age (healthy controls), years (mean, SD)		47.1 ± 12Range: 20–64

Gender (SAH), female		8 (57)

Gender (healthy controls), female		8 (57)

Admission H&H grade	1	9 (64)

2	4 (29)

3	1 (7)

Loss of consciousness		0 (0)

Admission APACHE II score		4 (2–5)

Admission radiological characteristics

mFisher scale	0	1 (7)

1	1 (7)

2	1 (7)

3	6 (43)

4	5 (36)

SAH sum score		13Range: 10–15

IVH sum score		0 (0–2)

Aneurysm location AcomA = anterior communicating artery		5 (36)

No aneurysm detected		9 (64)

Aneurysm size above 10 mm		0 (0)

Generalized cerebral edema		0 (0)

Intracerebral hematoma		0 (0)

Surgical procedures

Hydrocephalus requiring EVD/Shunt		0 (0)

Coiling		5 (36)

Clipping		0 (0)

No aneurysm		9 (64)

Hemicraniectomy		0 (0)

Complications

Pneumonia		0 (0)

Delayed cerebral infarction		0 (0)

Anemia requiring transfusion		0 (0)

Aneurysm rebleeding		0 (0)

Hyperosmolar therapy		0 (0)

Outcome characteristics

Length of hospital stay, days		19.5Range: 17–21

Discharge mRS	0	9 (64)

1	5 (36)

3‐month mRS	0	9 (64)

1	5 (36)

12‐months mRS	0	11 (79)

1	3 (21)

		N = 14 (%)

mFisher scale	4	5 (36)

SAH sum score		13Range: 10–15

IVH sum score		0 (0–2)

Aneurysm location AcomA = anterior communicating artery		5 (36)

No aneurysm detected		9 (64)

Aneurysm size above 10 mm		0 (0)

Generalized cerebral edema		0 (0)

Intracerebral hematoma		0 (0)

Surgical procedures

Hydrocephalus requiring EVD/Shunt		0 (0)

Coiling		5 (36)

Clipping		0 (0)

No aneurysm		9 (64)

Hemicraniectomy		0 (0)

Complications

Pneumonia		0 (0)

Delayed cerebral infarction		0 (0)

Anemia requiring transfusion		0 (0)

Aneurysm rebleeding		0 (0)

Hyperosmolar therapy		0 (0)

Outcome characteristics

Length of hospital stay, days		19.5Range: 17–21

Discharge mRS	0	9 (64)

1	5 (36)

3‐month mRS	0	9 (64)

1	5 (36)

12‐months mRS	0	11 (79)

1	3 (21)


	Model 1

Variable	B

Gender

Age

Self-esteem	–0.611

Condition (1 = materialism, –1 = control)	0.498

Self-esteem × Condition	0.487

	R2 = 0.176 F(3,123) = 8.780∗∗


Location	Tissue	Date of collection	Time period reflected	N	N males	N females

Newfoundland	Claws	April 2016	Winter	24	8	16

Whole blood	December 2013 to January 2014	Winter	35	30	5

Nuuk, Greenland	Claws	April 2014	Winter	33	6	29

Whole blood	April 2014	Late winter	34	6	29

East Bay Island	Claws	June to July 2014	Winter	109	0	109

Red blood cells	June to July 2014	Spring migration	108	0	108

Claws	June to July 2015	Winter	115	43	72

Red blood cells	June to July 2015	Spring migration	125	51	74

East Bay Island	Red blood cells	June to July 2014	Spring migration	108	0	108

Claws	June to July 2015	Winter	115	43	72

Red blood cells	June to July 2015	Spring migration	125	51	74


Suggestions from COECSA partners	Suggestions from United Kingdom partners

Program planning and design• There is need for continuous dialog and joint planning• COECSA to drive the process by demonstrating both demand and ownership• More opportunities for visits to the United Kingdom to “see how things are done”• LINK to facilitate setting up of more VISION 2020 twinning links in the region• LINK to provide more scope for interaction between the institutions in the ECSA region• Expand the scope of collaboration to include research, subspecialty programs, mentoring and instrumentsProgram implementation• Build capacity of editors of the scientific journal• Involve middle-level eye care cadres in the LINK• Training of examiners should be more intensive than just 1 day before the exams, “perhaps even organized in modules”• Make the partnership equal and mutual• Strengthen leadership of the COECSA and the LINKEvaluation• Gather evidence to demonstrate impact of the LINK• Strengthen monitoring and evaluation, and source funding for it	Program planning and design• Build on the successes of the partnership in future planningProgram implementation• COECSA needs to build develop staff to take lead in all the activities• Ensure the right people are on board for LINK activities• Encourage continuity for lead roles or smooth handover/transition when new persons take up roles• Aim to make each activity effective and evaluate effectiveness• Ensure United Kingdom facilitators have clarity on their roles• Improve frequency and regularity of communicationEvaluation• COECSA to strengthen reporting on LINK activities• Constantly evaluate if expectations of COECSA are being met


	STAV-AB xenograft	STAV-FCS xenograft	Localization

MESOTHELIAL AND EPITHELIAL MARKERS

Calretinin	++	++	Cytoplasm and nucleus

EMA	+	+(+)	Cell membrane

E-cadherin	+ (Focal)	+	Cell membrane

CK-HMW	++	++	Cytoplasm

Cytokeratin 7	+	++	Cytoplasm

Cytokeratin 8	−	−	Cytoplasm

Cam 5.2	+++	++	Cell membrane and cytoplasm

Syndecan-1	+	+	Cell membrane

MNF-116	+++	+++	Cell membrane and cytoplasm

DIFFERENTIATION-RELATED MARKERS

TrxR1	++	+++	Cytoplasm and nucleus

Integrin α5	+	+	Cytoplasm

HSP-47	+++	+++	Cell membrane and cytoplasm

Annexin-II	++	++	Cell membrane

MESENCHYMAL MARKERS

Vimentin	++	++	Cytoplasm

SM actin	+(+)	+	Cytoplasm

Syndecan-2	++	++	Cytoplasm

PROLIFERATION MARKER

Mib-1	>80%	40%	Nucleus

	STAV-AB xenograft	STAV-FCS xenograft

MESOTHELIAL AND EPITHELIAL MARKERS

Calretinin	++	++

EMA	+	+(+)

E-cadherin	+ (Focal)	+

CK-HMW	++	++

Cytokeratin 7	+	++

Cytokeratin 8	−	−

Cam 5.2	+++	++

Syndecan-1	+	+

MNF-116	+++	+++

DIFFERENTIATION-RELATED MARKERS

TrxR1	++	+++

Integrin α5	+	+

HSP-47	+++	+++

Annexin-II	++	++

MESENCHYMAL MARKERS

Vimentin	++	++

SM actin	+(+)	+

Syndecan-2	++	++

PROLIFERATION MARKER

Mib-1	>80%	40%

Localization

MESOTHELIAL AND EPITHELIAL MARKERS

Cytoplasm and nucleus

Cell membrane

Cell membrane

Cytoplasm

Cytoplasm

Cytoplasm

Cell membrane and cytoplasm

Cell membrane

Cell membrane and cytoplasm

DIFFERENTIATION-RELATED MARKERS

Cytoplasm and nucleus

Cytoplasm

Cell membrane and cytoplasm

Cell membrane

MESENCHYMAL MARKERS

Cytoplasm

Cytoplasm

Cytoplasm

PROLIFERATION MARKER

Nucleus


Antibody	Supplier	Western dilution

β-Actin	Sigma Aldrich	1 in 3000

CDK6	Santa Cruz	1 in 200

γH2AX (Ser139)	Cell Signaling	1 in 1000

Lamin a/c	Santa Cruz	1 in 500

MEK2	BD Biosciences	1 in 3000

PP1α	Bethyl Laboratory	1 in 1000

PP1β	Bethyl Laboratory	1 in 1000

PP1γ	Santa Cruz	1 in 200

p53	Oncogene	1 in 500

pATM (Ser1981)	Epitomics	1 in 500

p-p53 (Ser15)	Cell Signaling	1 in 500

Rad21 (SCC1)	abcam	1 in 1000

Rb	Santa Cruz	1 in 200

p73	Santa Cruz	1 in 100

p63	abcam	1 in 1000

p63(TA)	bioLegend	1 in 1000

Antibody	Supplier	Western dilution

p63(TA)	bioLegend	1 in 1000


Characteristic	Boys 8 years of age (n = 304)	Boys 9 years of age (n = 185)	Total boys (n = 489)

Growth and sexual maturation parameters

Age [years (mean ± SD)]	8.04 ± 0.10	9.02 ± 0.08	8.41 ± 0.49

Height [cm (mean ± SD)]	128.42 ± 5.91	133.00 ± 5.96	130.16 ± 6.32

Weight [kg (mean ± SD)]	26.49 ± 5.47	28.37 ± 5.65	27.20 ± 5.61

BMI (mean ± SD)	15.94 ± 2.30	15.94 ± 2.34	15.94 ± 2.31

Penile length [cm (mean ±SD)]a	5.49 ± 0.78	5.37 ± 0.67	5.45 ± 0.74

TV (mL) [no. (%)]b


Tocopherol	Cell type/Cancer model	Result	References

α-Tocopherol	Human retinal pigment epithelial cells (ARPE-19)	↑ Nrf2 protein levels, ↑ glutamate cysteine ligase, NQO1, HO-1, GST, SOD	[90]

γ-TmT	Prostate carcinogenesis in TRAMP male mice	↑ Nrf2 protein levels, ↑ GSTm1, UGT1A1, HO-1, catalase, SOD, glutathione peroxidase,	[43]

γ-TmT	Estrogen-induced mammary hyperplasia in female ACI rats	↑ Nrf2 protein levels	[92]

Tocopherol	Cell type/Cancer model	Result	References

γ-TmT	Prostate carcinogenesis in TRAMP male mice	↑ Nrf2 protein levels, ↑ GSTm1, UGT1A1, HO-1, catalase, SOD, glutathione peroxidase,	[43]

γ-TmT	Estrogen-induced mammary hyperplasia in female ACI rats	↑ Nrf2 protein levels	[92]


 	CBHI (26)	Non-CBHI (114)	t-test

Population density (per km2)	184.62	46.42	-2.571*

Poverty rate (%)	29.6	40.1	3.386**

Literacy rate (%)	79.00	64.2	-4.061**

% of labor non-agriculture	33.38	12.09	-5.868**

% HHs with electricity	73.7	41.87	-5.948**

Avg time to nearest health center (mins)	57.65	161	4.5322**

% pop Lao-tai (vs. ethnic minority)	56.09	26.93	-3.741**

% pop Buddhist	79.48	53.29	-3.71**


Characteristic	Amiodarone n=20	Metaprolol n=30	P value

AF%age	20%	26.7%	NS

Time of Development of AF	62.15+ 18	48.4+ 10.2	NS

Duration of AF	12.04+ 10.2	18.8+ 10.4	NS

Maximum Ventricular rate during AF	118.+ 30.4	148+ 22.2	NS

AF on discharge	1	3	NS

Length of hospital stay	12.7+ 4.5	13.2+ 5.2	NS

Cost of Care	1.17+ 0.12	1.18+0.10	NS

Characteristic	Amiodarone n=20	Metaprolol n=30	P value

Length of hospital stay	12.7+ 4.5	13.2+ 5.2	NS

Cost of Care	1.17+ 0.12	1.18+0.10	NS


Characteristics	Number of patients (%)

Sex

Male	42 (98)

Female	1 (2)

Age (years)

Range	39–80

Median	66

Stage

T1	1 (2)

T2	16 (37)

T3	9 (21)

T4	17 (40)

N

Yes	3 (7)

No	39 (91)

NA	1 (2)

M

Yes	6 (14)

No	36 (84)

NA	1 (2)

Histological type

Papillary	3 (7)

Colonic	25 (58.1)

Solid	5 (11.6)

Mucinous	10 (23.3)

Wood dust exposure

Yes	26 (60)

No	9 (21)

NA	8 (19)

Recurrence

Yes	24 (56)

No	17 (40)

NA	2 (4)

Outcome

Alive	16 (37)

Died of disease	16 (37)

Died of other causes	9 (21)

NA	2 (5)

Characteristics	Number of patients (%)

Mucinous	10 (23.3)

Wood dust exposure

Yes	26 (60)

No	9 (21)

NA	8 (19)

Recurrence

Yes	24 (56)

No	17 (40)

NA	2 (4)

Outcome

Alive	16 (37)

Died of disease	16 (37)

Died of other causes	9 (21)

NA	2 (5)


Before the phlebotomy training May 2014	After the phlebotomy training July 2014

CHC/CDC	Blood registrations	Blood rejections n (%)	Blood registrations	Blood rejections n (%)	p

A	7557	60 (0.79)	10 218	79 (0.77)	0.876

B	3973	45 (1.13)	4114	48 (1.17)	0.886

C	2321	38 (1.64)	2279	37 (1.62)	0.971

D	589	8 (1.36)	630	7 (1.11)	0.696

Before the phlebotomy training May 2014	After the phlebotomy training July 2014

CHC/CDC	Blood registrations	Blood rejections n (%)	Blood registrations	Blood rejections n (%)	p

D	589	8 (1.36)	630	7 (1.11)	0.696


Subgroup	No. of datasets	RR (95% CI)	I2	Pheterogeneity

Total	7	1.06 (0.89, 1.26)	25%	0.24

Geographical area


	K	AIC	ΔAICc	wi

All species

 Distance to road	2	2401.35	0	0.78

 Constant survival	1	2405.17	3.82	0.11

 Distance to edge	2	2406.59	5.24	0.06

 Distance to power lines	2	2407.04	5.69	0.05

 Macrohabitat type	5	2411.51	10.16	0.00

 Species	16	2424.29	25.86	0.00

BLGR

 Distance to edge	2	201.684	0	0.48

 Constant survival	1	207.16	1.19	0.26

 Distance to power lines	2	208.28	2.59	0.13

 Distance to road	2	209.26	3.15	0.10

 Macrohabitat type	5	212.60	6.48	0.02

BRTH

 Constant survival	1	273.10	0	0.37

 Distance to edge	2	274.11	1.01	0.22

 Distance to road	2	274.90	1.80	0.15

 Macrohabitat type	4	175.12	2.02	0.13

 Distance to power lines	2	275.229	2.13	0.13

INBU

 Distance to power lines	2	188.55	0	0.83

 Constant survival	1	193.48	4.93	0.07

 Macrohabitat type	5	194.29	5.74	0.05

 Distance to edge	2	195.51	6.96	0.03

 Distance to road	2	195.71	7.16	0.02

NOCA

 Constant survival	1	1225.21	0	0.44

 Distance to power lines	2	1226.68	1.47	0.21

 Distance to road	2	1227.02	1.81	0.18

 Distance to edge	2	1227.24	2.03	0.16

 Macrohabitat type	5	1232.03	6.81	0.01

WEVI

 Constant survival	1	76.03	0	0.59

 Distance to power lines	2	78.33	2.30	0.19

 Distance to edge	2	79.38	3.34	0.11

 Distance to road	2	79.39	3.36	0.11

 Macrohabitat type	4	89.69	13.65	0.00

	K	AIC	ΔAICc

All species

Distance to road	2	2401.35	0

Constant survival	1	2405.17	3.82

Distance to edge	2	2406.59	5.24

Distance to power lines	2	2407.04	5.69

Macrohabitat type	5	2411.51	10.16

Species	16	2424.29	25.86

BLGR

Distance to edge	2	201.684	0

Constant survival	1	207.16	1.19

Distance to power lines	2	208.28	2.59

Distance to road	2	209.26	3.15

Macrohabitat type	5	212.60	6.48

BRTH

Constant survival	1	273.10	0

Distance to edge	2	274.11	1.01

Distance to road	2	274.90	1.80

Macrohabitat type	4	175.12	2.02

Distance to power lines	2	275.229	2.13

INBU

Distance to power lines	2	188.55	0

Constant survival	1	193.48	4.93

Macrohabitat type	5	194.29	5.74

Distance to edge	2	195.51	6.96

Distance to road	2	195.71	7.16

NOCA

Constant survival	1	1225.21	0

Distance to power lines	2	1226.68	1.47

Distance to road	2	1227.02	1.81

Distance to edge	2	1227.24	2.03

Macrohabitat type	5	1232.03	6.81

WEVI

Constant survival	1	76.03	0

Distance to power lines	2	78.33	2.30

Distance to edge	2	79.38	3.34

Distance to road	2	79.39	3.36

Macrohabitat type	4	89.69	13.65


Characteristics	CMV infection	No CMV infection	p

N = 21	N = 65

Age, mean ± SD, y	51.4 ± 13.8	46.8 ± 15.6	0.244

Gender, male (%)	57.1	69.2	0.308

Type of transplant, Kidney /Kidney + pancreas (%)	24.4/25.0	75.6/75.0	0.977

Allograft function, (eGFR), mean ± SD

Day 30	44.0 ± 15.4	50.2 ± 23.3	0.347

Day 90	43.7 ± 17.4	52.6 ± 21.8	0.136

Blood transfusion, N Yes/No	12 /9	24 /38	0.140

Donor, D+/D- (%)	23.4/33.3	76.6/66.7	0.682

Pretransplant recipient CMV serostatus R+/R- (%)	22.4/33.1	77.6/66.9	0.410

The time of VGCV initiation after KTx (days); mean ± SD	9 ± 5	9 ± 5	0.905

The time of VGCV discontinuation after KTx (days); mean ± SD	94 ± 9	92 ± 14	0.458

Duration of antiviral prophylaxis (days); mean ± SD	85 ± 9	82 ± 15	0.382

total IgG concentration (g/L) < 7 / ≥7%

Day 0	0.0/26.3	100.0/73.7	0.571

Day 90	41.1/18.0	58.9/82.0	0.057

anti-CMV IgG titer (AU/ml) mean ± SD

Day 0	138 ± 113	168 ± 109	0.803

Day 90	113 ± 85	159 ± 109	0.087

leukocyte blood count (G/L) mean ± SD

Day 0	7.8 ± 2.4	7.9 ± 2.3	1.000

Day 30	8.5 ± 2.7	9.2 ± 4.0	0.800

Day 90	6.6 ± 4.9	6.5 ± 3.2	0.080

Induction therapy (%)			0.026

Yes basiliximab	25.8	74.2

Yes thymoglobulin	57.1	42.9

None	5.9	94.1

QuantiFERON-CMV assay (IU/mL) < 0.2/≥0.2 (%)

All time points used	42.9/15.6	57.1/84.4	0.005

Day 7	39.0/14.6	61.0/85.4	0.015

Day 30	40.7/9.1	59.3/90.9	0.003

Day 90	42.8/16.4	57.2/83.6	0.008

lymphocyte blood count (G/L) < 0.8/≥0.8 (%)

D	0.0/25.	100.0/74.	1.


Characteristic	Total Group (n = 270)	IR (n = 183)	ID/IDA (n = 87)	p-Value 1

Age (years)	25.9 ± 5.0	26.3 ± 4.9	25.3 ± 5.2	0.131


	Gene name	Gene Accession number	Score (d)	Log2 expression ratio

Genes mainly expressed in skeletal muscle	Nebulette (Actin-binding Z-disk protein)	NM_006393	42.93	3.81

	Troponin I, fast skeletal muscle (Troponin I, fast-twitch isoform)	NM_003282	34.39	2.60

	Huntingtin interacting protein 1 (HIP-I)	NM_005338	33.55	2.59

	Myosin light chain 2a	NM_021223	32.80	3.26

	Troponin C, skeletal muscle	NM_003279	32.21	2.45

	Myosin light chain 2	NM_013292	29.25	3.06

	Myosin heavy chain, skeletal muscle, perinatal	NM_002472	28.14	2.80

	Troponin T, fast skeletal muscle isoforms	NM_006757	26.04	2.71

	Myosin heavy chain, cardiac muscle beta isoform	NM_000257	24.94	3.12

	Actin, alpha skeletal muscle (Alpha-actin 1)	NM_001100	24.21	3.50

	Troponin C, slow	NM_003280	21.31	2.54

	Nebulin	NM_004543	20.17	2.78

	Smoothelin	NM_134269	19.50	1.32

	Tropomyosin 1 alpha chain (Alpha-tropomyosin)	NM_000366	18.92	1.99

	Myotilin	NM_006790	18.07	1.56

Genes mainly expressed in MCF-7 cells	Actin, cytoplasmic 2 (Gamma-actin)	NM_001614	-30.24	-2.58

	Elongation factor 1-beta (EF-1-beta)	NM_001959	-22.14	-1.26

	Actin binding protein anillin,	NM_018685	-20.12	-1.13

	Keratin, type I cytoskeletal 18	NM_000224	-18.78	-2.83

	Ankyrin 3 (ANK-3) (Ankyrin G)	NM_020987	-16.43	-2.17

	Gamma-parvin	NM_022141	-16.30	-1.03

	Spectrin beta chain, brain 2 (Spectrin, non-erythroid beta chain 2) (Beta-III spectrin)	NM_006946	-16.28	-0.84

	Coronin 1B (Coronin 2)	NM_020441	-15.97	-0.84

	Beta-centractin (Actin-related protein 1B) (ARP1B)	NM_005735	-15.79	-1.40

	NB thymosin beta	NM_021992	-14.92	-1.42

	Coronin 2A (WD-repeat protein 2) (IR10)	NM_052820	-14.39	-1.24

	ARP2/3 complex 16 kDa subunit (P16-ARC) (Actin-related protein 2/3 complex subunit 5)	NM_005717	-13.74	-1.06

	Tight junction protein ZO-1 (Zonula occludens 1 protein) (Zona occludens 1 protein) (Tight junction protein 1)	NM_003257	-13.70	-1.28

	Transcription factor 7 (T-cell-specific transcription factor 1) (TCF- 1) (T-cell factor 1)	NM_003202	-13.60	-0.67

	Catenin delta-1 (p120 catenin) (p120(ctn)) (Cadherin-associated Src substrate) (CAS) (p120(cas))	NM_001331	-13.60	-0.77

	Gene name	Gene Accession number	Score (d)	Log2 expression ratio

	Myosin heavy chain, skeletal muscle, perinatal	NM_002472	28.14	2.80

	Troponin T, fast skeletal muscle isoforms	NM_006757	26.04	2.71

	Myosin heavy chain, cardiac muscle beta isoform	NM_000257	24.94	3.12

	Actin, alpha skeletal muscle (Alpha-actin 1)	NM_001100	24.21	3.50

	Troponin C, slow	NM_003280	21.31	2.54

	Nebulin	NM_004543	20.17	2.78

	Smoothelin	NM_134269	19.50	1.32

	Tropomyosin 1 alpha chain (Alpha-tropomyosin)	NM_000366	18.92	1.99

	Myotilin	NM_006790	18.07	1.56

Genes mainly expressed in MCF-7 cells	Actin, cytoplasmic 2 (Gamma-actin)	NM_001614	-30.24	-2.58

	Elongation factor 1-beta (EF-1-beta)	NM_001959	-22.14	-1.26

	Actin binding protein anillin,	NM_018685	-20.12	-1.13

	Keratin, type I cytoskeletal 18	NM_000224	-18.78	-2.83

	Ankyrin 3 (ANK-3) (Ankyrin G)	NM_020987	-16.43	-2.17

	Gamma-parvin	NM_022141	-16.30	-1.03

	Spectrin beta chain, brain 2 (Spectrin, non-erythroid beta chain 2) (Beta-III spectrin)	NM_006946	-16.28	-0.84

	Coronin 1B (Coronin 2)	NM_020441	-15.97	-0.84

	Beta-centractin (Actin-related protein 1B) (ARP1B)	NM_005735	-15.79	-1.40

	NB thymosin beta	NM_021992	-14.92	-1.42

	Coronin 2A (WD-repeat protein 2) (IR10)	NM_052820	-14.39	-1.24

	ARP2/3 complex 16 kDa subunit (P16-ARC) (Actin-related protein 2/3 complex subunit 5)	NM_005717	-13.74	-1.06

	Tight junction protein ZO-1 (Zonula occludens 1 protein) (Zona occludens 1 protein) (Tight junction protein 1)	NM_003257	-13.70	-1.28

	Transcription factor 7 (T-cell-specific transcription factor 1) (TCF- 1) (T-cell factor 1)	NM_003202	-13.60	-0.67

	Catenin delta-1 (p120 catenin) (p120(ctn)) (Cadherin-associated Src substrate) (CAS) (p120(cas))	NM_001331	-13.60	-0.77


Gene IDa	Primers (5′-3′)	Accession No.	Amplicon length

Act- β	Forward: CGGCATCGAGGACAGGATReverse: CATCGTACTCCTGCTTGCTGAT	NM_173979.3	169

GAPDH	Forward: CCTGCCCGTTCGACAGATAReverse: GGCGACGATGTCCACTTTG	NM_001034034.1	150

FAU	Forward: CCGCATGCTTGGAGGTAAAGReverse: CACAACATTGACAAAGCGCC	NM_174731.3	154

RPS9	Forward: CCGCATGCTTGGAGGTAAAGReverse: CACAACATTGACAAAGCGCC	NM_001101152.2	188

HPRT1	Forward:GGATTACATCAAAGCACTGAACAReverse: CATTGTCTTCCCAGTGTCAATT	NM_001034035	194

Gene IDa	Primers (5′-3′)	Accession No.	Amplicon length

HPRT1	Forward:GGATTACATCAAAGCACTGAACAReverse: CATTGTCTTCCCAGTGTCAATT	NM_001034035	194


Characteristic/subcategory	Discomfort of acupuncture: No. (%)	No discomforta	Slight discomforta

No	Slight	Moderate to severe	OR (95% CI)	P value	OR (95% CI)	P value

Age


Characteristics	Category	NSSIs	p-value

Present	Absent

Nationality	Nepalese	87 (42.4)	118 (57.6)	0.653

	Indian	3 (60.0)	2 (40.0)


Item	Descriptions

Number of stations	12

Date span 	1–30 May 2015; 1–30 July 2016

Signal selection	GPS: L1/L2/L5; GLONASS: L1/L2; BeiDou: B1/B2/B3; Galileo: E1/E5a/E5b

Sampling interval	30 s

Elevation cut off	10°

Time system	GPS time

Tropospheric delay	Dry component: corrected with GPT model [26], wet component: estimated as random-walk process, GMF mapping function applied.

First order ionospheric delay	Single-frequency SPP:

GPS/GLONASS: Klobuchar model

BDS: Klobuchar model [27]

Galileo: The NeQuick model [28]

Dual-frequency: First order eliminated by ionosphere-free combination

Relativistic effect	IERS2010 [29]

Sagnac effect	IERS2010 [29]

Phase wind-up effect	Corrected [30]

Satellite PCO and PCV	GPS and GLONASS: Fixed to igs08_1861.atx values;

Tide displacement	IERS2010 [29]

Station reference coordinates	IGS SINEX solutions or daily GPS-only PPP solutions

Item

Number of stations

Date span

Signal selection

Sampling interval

Elevation cut off

Time system

Tropospheric delay

First order ionospheric delay

Relativistic effect

Sagnac effect

Phase wind-up effect

Satellite PCO and PCV

Tide displacement

Station reference coordinates

Descriptions

12

1–30 May 2015; 1–30 July 2016

GPS: L1/L2/L5; GLONASS: L1/L2; BeiDou: B1/B2/B3; Galileo: E1/E5a/E5b

30 s

10°

GPS time

Dry component: corrected with GPT model [26], wet component: estimated as random-walk process, GMF mapping function applied.

Single-frequency SPP:

GPS/GLONASS: Klobuchar model

BDS: Klobuchar model [27]

Galileo: The NeQuick model [28]

Dual-frequency: First order eliminated by ionosphere-free combination

IERS2010 [29]

IERS2010 [29]

Corrected [30]

GPS and GLONASS: Fixed to igs08_1861.atx values;

IERS2010 [29]

IGS SINEX solutions or daily GPS-only PPP solutions


Ethnic group	α-globin genotypes	Total

- -α3.7/αα	- -α4.2/αα	- -SEA/αα

Malay (n = 315)	32	0	1	33

Chinese (n = 73)	2	1	1	4

Indian (n = 12)	0	0	0	0

Total (n = 400)	34	1	2	37


Strain	D	Yxs	rs	rCO2	rO2	retoh	racet	RQ	Cs	Cbalance	Totsant

	(h-1)	(g g-1)	(mmol g biomass-1h-1)	(rCO2/rO2)	(mM)	(%)	(mg 24 h-1l-1)


PPI Dataset	Methods	Precision

DIP	CDUN	0.6

CSO	0.497

Cluster ONE	0.337

COAN	0.41

COACH	0.307

CMC	0.485

HUNTER	0.852

MCODE	0.423

TransClust	0.13

SpecClust	0.122

MIPS	CDUN	0.438

CSO	0.391

Cluster ONE	0.273

COAN	0.356

COACH	0.239

CMC	0.335

HUNTER	0.538

MCODE	0.365

TransClust	0.145

SpecClust	0.095

STRING	CDUN	0.446

Cluster ONE	0.13

COACH	0.181

HUNTER	0.5

MCODE	0.079

TransClust	0.11

SpecClust	0.066


Species Name	LC50/EC50 (95% Confidence Interval Limit)	Study

Oreochromis niloticus	3760 mg∙L−1 (2990–4010)	Omoregie et al. (2009) [39]

Chironomus yoshimatsui	1520 mg∙L−1	Kegley et al. (2014) [40]

Viviparus bengalensis	2280 mg∙L−1	Kegley et al. (2014) [40]

Radix luteola	3000 mg∙L−1	USEPA, (2015) [41]


	2010 auditn = 82	2011 re-auditn = 140

Patients who had at least one neuroimaging procedure (through MAS or previous), n (%)	56 (68)	106 (76)

Neuroimaging requested through MAS, n (%)	48 (59)	88 (63)

Previous neuroimaging, n (%)	8 (9)	18 (13)

Patients who declined assessment/scan, n (%)	13 (16)	29 (21)

Patients with documented reasons for not having neuroimaging (unable to tolerate scan, moved out of area, died), n (%)	0 (0)	4 (3)

Patients with no reason documented for not having neuroimaging, n (%)	13 (16)	1 (1)

Of the patients who did not have any neuroimaging, proportion with no reason documented, n/N (%)	13/26 (50)	1/34 (3)

Type of neuroimaging performed (through MAS and previous), n/N (%)

CT scan	49/56 (88)	92/106 (87)

MRI scan	5/56 (9)	14/106 (13)

Other (FDG-PET/CT, HMPAO-SPECT)	2/56 (4)	0/106 (0)

Coronal imaging on CT scans requested through MAS, n/N (%)	Data not available	45/78 (58)

Length of time between scan requests and scan appointments, days

Range	6-42	11-71

Mean	22	30

Range across different sectors of patients who had a neuroimaging procedure, %	33-100	58-84

	2010 auditn = 82	2011 re-auditn = 140

CT scan	49/56 (88)	92/106 (87)

MRI scan	5/56 (9)	14/106 (13)

Other (FDG-PET/CT, HMPAO-SPECT)	2/56 (4)	0/106 (0)

Coronal imaging on CT scans requested through MAS, n/N (%)	Data not available	45/78 (58)

Length of time between scan requests and scan appointments, days

Range	6-42	11-71

Mean	22	30

Range across different sectors of patients who had a neuroimaging procedure, %	33-100	58-84


VA outcome	Fox (n = 19)	Clark (n = 36)	Al-Mezaine (n = 17)	Shirodkar (n = 26)	Overall (n = 98)

≥2	9 (47.	18	5 (29.	13	45 (4


Parameter	Definition

N	Number of individuals in the population

Z	Probability to reproduce by self-fertilization

w	Fitness of an individual

n	Number of TE copies in the genome

si	Effect of insertion i on fitness

μs	Average effect of TE insertions on fitness

σs	Standard deviation of the effect on fitness

Ps > 0	Proportion of TE insertions that improve the fitness

u	Replicative transposition rate

v	Deletion rate

ai	Activity of a copy i (ability to produce the transposition machinery)

m	Mutation rate (toward a less active copy)

σm	Standard deviation of the effect of a mutation on activity

Parameter	Definition

si	Effect of insertion i on fitness

μs	Average effect of TE insertions on fitness

σs	Standard deviation of the effect on fitness

Ps > 0	Proportion of TE insertions that improve the fitness

u	Replicative transposition rate

v	Deletion rate

ai	Activity of a copy i (ability to produce the transposition machinery)

m	Mutation rate (toward a less active copy)

σm	Standard deviation of the effect of a mutation on activity


Gene list	N genes	Proportion of genome	SNP heritability (P value)

SNPs	Mb	All samples	Infliximab+Adalimumab

Whole genome	—	1	1	0.18 (0.02)	0.36 (0.005)

Drug metabolism*	215	0.07	0.10	0.05 (0.3)	0.04 (0.09)

Immune-related†	6,001	0.65	0.58	0.07 (0.2)	0.21 (0.01)

TNF/TNFR pathway‡	333	0.11	0.14	0.05 (0.04)	0.02 (0.3)

CD84 coexpression (ImmGen)	200	0.08	0.11	0 (0.5)	0 (0.5)

Gene list	N genes	Proportion of genome

SNPs	Mb

Whole genome	—	1	1

Drug metabolism*	215	0.07	0.10

Immune-related†	6,001	0.65	0.58

TNF/TNFR pathway‡	333	0.11	0.14

CD84 coexpression (ImmGen)	200	0.08	0.11


Sample

MWS-1 MWS-2 MWS-3

MWS-4 MWS-5 MWS-6

MWS-7 MWS-8 MWS-9


Human protein	Targeting DNA virus families	Targeting RNA virus families

HNRPK – heterogeneous nuclear ribonucleoprotein K	Asfarviridae, Herpesviridae, Papillomaviridae, Poxviridae	Arteriviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

YBOX1 – nuclease‐sensitive element‐binding protein 1	Herpesviridae, Papillomaviridae, Polyomaviridae, Poxviridae	Arteriviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae

EF1A1 – elongation factor 1‐alpha 1	Herpesviridae, Papillomaviridae, Poxviridae	Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae

IMA1 – Importin subunit alpha‐1	Adenoviridae, Herpesviridae, Papillomaviridae, Parvoviridae, Polyomaviridae, Poxviridae	Coronaviridae, Orthomyxoviridae, Paramyxoviridae

ADT2 – ADP/ATP translocase 2	Herpesviridae, Papillomaviridae, Poxviridae	Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae,Togaviridae

TBA1C – Tubulin alpha‐1C chain	Herpesviridae, Papillomaviridae, Poxviridae	Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae

ROA1 – heterogeneous nuclear ribonucleoprotein A1	Herpesviridae, Papillomaviridae, Poxviridae	Arteriviridae, Coronaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Togaviridae

GRP78 – 78 kDa glucose‐regulated protein	Herpesviridae, Papillomaviridae, Poxviridae	Bunyaviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Togaviridae

TBB5 – Tubulin beta chain	Herpesviridae, Poxviridae	Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae

P53 – cellular tumor antigen p53	Adenoviridae, Herpesviridae, Papillomaviridae, Parvoviridae, Polyomaviridae	Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

NPM – nucleophosmin	Adenoviridae, Herpesviridae, Papillomaviridae, Poxviridae	Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

GBLP – guanine nucleotide‐binding protein subunit beta‐2‐like 1	Adenoviridae, Herpesviridae, Papillomaviridae, Poxviridae	Arteriviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

TCPG – T‐complex protein 1 subunit gamma	Adenoviridae, Herpesviridae, Papillomaviridae	Arenaviridae, Bunyaviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae

EF1A3 – putative elongation factor 1‐alpha‐like 3	Herpesviridae, Papillomaviridae, Poxviridae	Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae

HNRPC – heterogeneous nuclear ribonucleoproteins C1/C2	Herpesviridae, Papillomaviridae, Poxviridae	Arteriviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Togaviridae

TCPE – T‐complex protein 1 subunit epsilon	Adenoviridae, Herpesviridae	Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae

HS90B – heat shock protein HSP 90‐beta	Herpesviridae, Poxviridae	Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

HNRH1 – heterogeneous nuclear ribonucleoprotein H	Herpesviridae, Papillomaviridae	Arteriviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae

TBA1A – Tubulin alpha‐1A chain	Herpesviridae, Poxviridae	Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae

HNRPF – heterogeneous nuclear ribonucleoprotein F	Herpesviridae, Papillomaviridae	Arteriviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae

ROA2 – heterogeneous nuclear ribonucleoproteins A2/B1	Herpesviridae, Poxviridae	Arteriviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

Human protein

HNRPK – heterogeneous nuclear ribonucleoprotein K

YBOX1 – nuclease‐sensitive element‐binding protein 1

EF1A1 – elongation factor 1‐alpha 1

IMA1 – Importin subunit alpha‐1

ADT2 – ADP/ATP translocase 2

TBA1C – Tubulin alpha‐1C chain

ROA1 – heterogeneous nuclear ribonucleoprotein A1

GRP78 – 78 kDa glucose‐regulated protein

TBB5 – Tubulin beta chain

P53 – cellular tumor antigen p53

NPM – nucleophosmin

GBLP – guanine nucleotide‐binding protein subunit beta‐2‐like 1

TCPG – T‐complex protein 1 subunit gamma

EF1A3 – putative elongation factor 1‐alpha‐like 3

HNRPC – heterogeneous nuclear ribonucleoproteins C1/C2

TCPE – T‐complex protein 1 subunit epsilon

HS90B – heat shock protein HSP 90‐beta

HNRH1 – heterogeneous nuclear ribonucleoprotein H

TBA1A – Tubulin alpha‐1A chain

HNRPF – heterogeneous nuclear ribonucleoprotein F

ROA2 – heterogeneous nuclear ribonucleoproteins A2/B1

Targeting DNA virus families	Targeting RNA virus families

Asfarviridae, Herpesviridae, Papillomaviridae, Poxviridae	Arteriviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

Herpesviridae, Papillomaviridae, Polyomaviridae, Poxviridae	Arteriviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae

Herpesviridae, Papillomaviridae, Poxviridae	Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae

Adenoviridae, Herpesviridae, Papillomaviridae, Parvoviridae, Polyomaviridae, Poxviridae	Coronaviridae, Orthomyxoviridae, Paramyxoviridae

Herpesviridae, Papillomaviridae, Poxviridae	Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae,Togaviridae

Herpesviridae, Papillomaviridae, Poxviridae	Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae

Herpesviridae, Papillomaviridae, Poxviridae	Arteriviridae, Coronaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Togaviridae

Herpesviridae, Papillomaviridae, Poxviridae	Bunyaviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Togaviridae

Herpesviridae, Poxviridae	Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae, Togaviridae

Adenoviridae, Herpesviridae, Papillomaviridae, Parvoviridae, Polyomaviridae	Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

Adenoviridae, Herpesviridae, Papillomaviridae, Poxviridae	Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

Adenoviridae, Herpesviridae, Papillomaviridae, Poxviridae	Arteriviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

Adenoviridae, Herpesviridae, Papillomaviridae	Arenaviridae, Bunyaviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae

Herpesviridae, Papillomaviridae, Poxviridae	Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae

Herpesviridae, Papillomaviridae, Poxviridae	Arteriviridae, Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, Togaviridae

Adenoviridae, Herpesviridae	Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae

Herpesviridae, Poxviridae	Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae

Herpesviridae, Papillomaviridae	Arteriviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae

Herpesviridae, Poxviridae	Arenaviridae, Bunyaviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Reoviridae

Herpesviridae, Papillomaviridae	Arteriviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae

Herpesviridae, Poxviridae	Arteriviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, Paramyxoviridae, Togaviridae


Stage of Lactation (Month)

Maternal age (years)

Maternal BMI

Parity

Infant sex (Male/Female)

Infant birth weight (kg)

Infant body length (cm)


Group	E1′ (MPa)	E2′ (MPa)	ts (min)	G∞	R2


Characteristics	Yes n (%)	Non-compliance to HPV vaccination

Prevalence	p value	Odds Ratio (CI 95 %)

Parent’s religion	Protestant	262 (44,1 %)	17,9 %	ns	1,03 (0,576–1,45)

Non protestant	332 (55,9 %)	17,5 %		1

Parent’s schooling	Elementary school	203 (26,8 %)	16,7 %	ns	0,98 (0,71–1,73)

High school / higher	554 (73,2 %)	16,9 %		1

Monthly household income	Up to I$ 400	353 (49,5 %)	16,1 %	ns	1,02 (0,61–1,41)

More than I$ 400	360 (50,5 %)	18,6 %		1

Type of school	Private school	99 (12,5 %)	43,7 %	0,003	4,51 (1,63–12,46)

Public school	698 (87,5 %)	15,9 %		1

Correct answers in 10 knowledge questions	Less than 50 %	287 (38,8 %)	20,2 %	0,02	1,60 (1,05–2,42)

More than 50 %	453 (61,2 %)	13,6 %		1

Knowing that HPV infections is not rare	Wrong	400 (50,2 %)	21,5 %	0,001	1,81 (1,24–2,64)

Right	397 (49,8 %)	13,1 %		1

Knowing the recommended age group for vaccination	Wrong	700 (87,8 %)	18,3 %	0,04	1,94 (1,02–3,86)

Right	97 (12,2 %)	10,3 %		1

Knowing that the vaccine is effective in preventing HPV	Wrong	301 (37,7 %)	20,6 %	0,01	1,62 (1,08–2,41)

Right	496 (62,3 %)	14,0 %		1

Knowing that the vaccine prevents cervical cancer	Wrong	152 (19,1 %)	24,4 %	0,01	1,73 (1,14–2,84)

Right	645 (80,9 %)	15,6 %		1

Knowing that HPV is a STD	Wrong	248 (31,1 %)	17,7 %	ns	1,04 (0,73–1,66)

Right	549 (68,9 %)	17,1 %		1

Knowing that men are affected by HPV	Wrong	449 (56,3 %)	18,0 %	ns	1,12 (0,71–1,60)

Right	348 (43,7 %)	16,3 %		1

Knowing that HPV causes genital warts	Wrong	484 (60,7 %)	18,8 %	ns	1,41 (0,92–2,17)

Right	313 (39,3 %)	15,0 %		1

Knowing that HPV causes CC	Wrong	152 (19,1 %)	19,7 %	ns	1,35 (0,85–2,16)

Right	645 (80,9 %)	16,7 %		1

Knowing that the HPV infection is usually asymptomatic	Wrong	610 (76,5 %)	16,1 %	ns	0,71 (0,43–1,06)

Right	187 (23,5 %)	21,4 %		1

Knowing that there is no curative treatment for HPV	Wrong	731 (91,7 %)	17,6 %	ns	1,53 (0,63–3,67)

Right	66 (8,3 %)	13,6 %		1

Knowing that men are affected by HPV	Right	348 (43,7 %)	16,3 %		1

Knowing that HPV causes genital warts	Wrong	484 (60,7 %)	18,8 %	ns	1,41 (0,92–2,17)

Right	313 (39,3 %)	15,0 %		1

Knowing that HPV causes CC	Wrong	152 (19,1 %)	19,7 %	ns	1,35 (0,85–2,16)

Right	645 (80,9 %)	16,7 %		1

Knowing that the HPV infection is usually asymptomatic	Wrong	610 (76,5 %)	16,1 %	ns	0,71 (0,43–1,06)

Right	187 (23,5 %)	21,4 %		1

Knowing that there is no curative treatment for HPV	Wrong	731 (91,7 %)	17,6 %	ns	1,53 (0,63–3,67)

Right	66 (8,3 %)	13,6 %		1


Population	IDF guideline recommendation	Assessment in study

All acne patients	Assign treatment according to acne severity	Not assessed in study: could not be evaluated by computerized query (Disease severity not stated within diagnosis field)

All acne patients	Progress gradually between treatment lines	Correctness of treatment progression assessed for treatment courses of distinct acne medications (see Table 4)

Patients treated with oral retinoids	Rule out psychiatric diagnoses prior to treatment initiation, and refer to psychiatrist if necessary	Not assessed in study: information not available in computerized patient records

Patients treated with oral retinoids	Monitor laboratory test values (liver enzymes, plasma lipid profile) before and during treatment.	Not assessed in study: computerized laboratory test records were not available for cross analysis between databases.

Patients treated with oral retinoids	Prescribe supportive care if necessary.	Concomitant prescribing or dispensing of supportive care medications was assessed (see Table 5).

Patients treated with oral retinoids	Restrict patient participation in strenuous physical activity by temporarily adjusting medical profile.	Not assessed in study: documentation of temporary change in medical profile was not available after reinstatement of permanent profile.

Female patients treated with oral retinoids (teratogenic)	- Rule out pregnancy (laboratory test).	Documented concomitant prescribing or dispensing of oral contraceptives to female patients receiving OI’s.

- Inform the patient of potential hazards and explain about required birth control measures.

- Have the patient sign a statement and file in their medical record (see background).

Female patients treated with oral retinoids (teratogenic)	- Have the patient sign a statement and file in their medical record (see background).	Documented concomitant prescribing or dispensing of oral contraceptives to female patients receiving OI’s.


Characteristic	No. of patients	%

Patients evaluable	70	100

Age, years

 Median (range)	65 (32–75)

Sex

 Male	41	58.5

 Female	29	41.5

Response to prior chemotherapy

 Yes	44	63

 No	26	37

Status of primary tumor

 Resected	25	36

 Unresected	45	64

Tumor histology

 Diffuse	33	47.2

 Intestinal	29	41.4

 Unknown	8	11.4

ECOG PS

 0	10	14.5

 1	40	57

 2	20	28.5

Number of metastatic sites

 1	17	24

 2	32	46

 3	21	30

Site of metastases

 Liver	48	68.5

 Nodes	41	58.5

 Peritoneum	41	58.5

 Lung	13	18.5

 Bone	6	8.5

PFS under first-line chemotherapy

 ≥ 6 months	42	60

 < 6 months	28	40

Chemotherapy-free interval

 > 3 months	38	54

 < 3 months	32	46

Characteristic	No. of patients

Patients evaluable	70

Age, years

Median (range)	65 (32–75)

Sex

Male	41

Female	29

Response to prior chemotherapy

Yes	44

No	26

Status of primary tumor

Resected	25

Unresected	45

Tumor histology

Diffuse	33

Intestinal	29

Unknown	8

ECOG PS

0	10

1	40

2	20

Number of metastatic sites

1	17

2	32

3	21

Site of metastases

Liver	48

Nodes	41

Peritoneum	41

Lung	13

Bone	6

PFS under first-line chemotherapy

≥ 6 months	42

< 6 months	28

Chemotherapy-free interval

> 3 months	38

< 3 months	32


	Lipid emulsion (n = 16)	Control (n = 11)

Initiation of enteral nutrition (h)	10.63 ± 5.49	9.27 ± 6.69

Age at feeds >100 mL/kg per day (days)	11.69 ± 4.75	7.55 ± 3.77*

Period of parenteral nutrition (days)	12.75 ± 5.84	8.91 ± 3.70*

Human milk/enteral nutrition at 2 weeks (%)	91.29 ± 21.55	73.84 ± 39.72

Lipid emulsion

 Initiation (day)	5.13 ± 2.31	–

 Amount of initiation (g/kg per day)	0.60 ± 0.17	–

 Period (days)	6.88 ± 3.61	–

 Total amount of infusion (g/kg)	3.89 ± 3.22	–

	Lipid emulsion (n = 16)

Initiation of enteral nutrition (h)	10.63 ± 5.49

Age at feeds >100 mL/kg per day (days)	11.69 ± 4.75

Period of parenteral nutrition (days)	12.75 ± 5.84

Human milk/enteral nutrition at 2 weeks (%)	91.29 ± 21.55

Lipid emulsion

Initiation (day)	5.13 ± 2.31

Amount of initiation (g/kg per day)	0.60 ± 0.17

Period (days)	6.88 ± 3.61

Total amount of infusion (g/kg)	3.89 ± 3.22


Indicator	Participantsa	P

With probable depression at baseline(n = 309)	Without probable depression at baseline(n = 266)

Treatment outcome, no. (%)

Treatment success	269 (87.1)	257 (96.6)	< 0.001

Treatment failure	4 (1.3)	2 (0.8)	ND

Treatment default	12 (3.9)	2 (0.8)	< 0.05

Death	24 (7.8)	5 (1.9)	< 0.01

Quality-of-life score, mean(SD)b,c

At baseline before tuberculosis treatment	4.7 (2.7)	5.7 (2.4)	< 0.001

After 6 months of treatment	5.0 (2.4)	6.0 (2.2)	< 0.001

Disability score, median(IQR)c,d

At baseline before tuberculosis treatment	30 (16)	18 (8)	< 0.001

After 6 months of treatment	22 (19)	14 (4)	< 0.001

Indicator	Participantsa	P

With probable depression at baseline(n = 309)	Without probable depression at baseline(n = 266)

Disability score, median(IQR)c,d

At baseline before tuberculosis treatment	30 (16)	18 (8)	< 0.001

After 6 months of treatment	22 (19)	14 (4)	< 0.001


	Age group, years

Demographics	< 65	≥65

Participants, n	9,883	3,566

Person-years,	124,466	50,269

Deaths (all causes), n	460	1,379

Deaths (CVD), n (% of all deaths)	119 (26)	592 (43)

Mean age at baseline, years (± SD)	45.8 (11.3)	73.1 (6.1)

Mean body mass index, kg/m2 (± SD)	29.5 (4.0)	29.0 (3.9)

Mean waist circumference, cm (± SD)	95.3 (10.0)	95.1 (10.3)

Mean SBP, mmHg (± SD)	142.5 (17.3)	160.9 (22.3)

Mean DBP, mmHg (± SD)	85.1 (11.0)	87.7 (12.9)

Mean serum triglycerides, mmol/L (± SD)	2.8 (1.4)	2.6 (1.1)

Mean serum glucose, mmol/L (± SD)	5.6 (1.7)	6.3 (2.4)

Mean serum HDL, mmol/L (± SD)	1.1 (0.3)	1.2 (0.3)

Mean percentage of people taking diabetes medication (± SD)	3.8 (0.04)	12.6 (0.1)

Mean percentage of people taking BP medication (± SD)	11.5 (0.1)	33 (0.3)

Mean percentage of current smokers (± SD)	32.2 (0.3)	15.9 (0.1)

Mean percentage of sedentary occupational work (± SD)	28 (0.2)	45 (0.3)

Mean percentage of college or university education (± SD)	18 (0.2)	5 (0.05)

Participants' PA levelsb, %

 Inactive	9	19

 Low	38	39

 Moderate	27	29

 High	26	12

	Age group, years

Demographics	< 65

Participants, n	9,883

Person-years,	124,466

Deaths (all causes), n	460

Deaths (CVD), n (% of all deaths)	119 (26)

Mean age at baseline, years (± SD)	45.8 (11.3)

Mean body mass index, kg/m2 (± SD)	29.5 (4.0)

Mean waist circumference, cm (± SD)	95.3 (10.0)

Mean SBP, mmHg (± SD)	142.5 (17.3)

Mean DBP, mmHg (± SD)	85.1 (11.0)

Mean serum triglycerides, mmol/L (± SD)	2.8 (1.4)

Mean serum glucose, mmol/L (± SD)	5.6 (1.7)

Mean serum HDL, mmol/L (± SD)	1.1 (0.3)

Mean percentage of people taking diabetes medication (± SD)	3.8 (0.04)

Mean percentage of people taking BP medication (± SD)	11.5 (0.1)

Mean percentage of current smokers (± SD)	32.2 (0.3)

Mean percentage of sedentary occupational work (± SD)	28 (0.2)

Mean percentage of college or university education (± SD)	18 (0.2)

Participants' PA levelsb, %

Inactive	9

Low	38

Moderate	27

High	26


	History of diagnosed diabetes

	Overall	No	Yes

N	1873	1587	286

Age (years; mean ± SE)	73.0 ± 0.14	73.0 ± 0.15	73.1 ± 0.36

Sex (% female)	48.7	48.7	48.6

Education (years; mean ± SE)	4.9 ± 0.11	4.9 ± 0.12	5.1 ± 0.30

Marital status (%married or living with partner)	66.8	67.2	64.3

Smoking status (%current)	19.4	19.7	17.8

Functional status (%)

High	47.7	50.5	32.5

Middle	44.6	43.0	53.8

Low	7.6	6.6	13.6

Heart disease (% yes)	23.4	21.6	32.9

Hypertension (% yes)	39.6	37.3	52.3

Stroke (% yes)	7.6	6.4	14.4

Number of other conditions† (%)

0	49.6	52.1	35.3

1	32.8	32.4	34.5

≥ 2	17.7	15.4	30.2

Duration of diabetes (years; mean ± SE)			10.0 ± 0.55

Use Insulin (% yes)			19.7


	Masamoto et al. [5]	Lee et al. [6]	Matsuda et al. [7]	Oswal and Agarwal [8]	Ville et al. [11]	Ville et al. [11]	Present case

Warfarin dose (mg/day)	3.5	6–7	NA	NA	3–6	5–6	3–4.5

Start of warfarin (weeks)	20	14	14	24	26	15	12

PT (INR)	2.7–2.9	2.2–3.0	NA	NA	1.7–2.5	0.7–1.9	1.5–2.0

GA at diagnosis (weeks)	23	23	31	24	32	29	31

Hemorrhage site	Subdural	Subdural	Subdural	Subdural	Intraventricular	Intraventricular	Subdural

Delivery (weeks)	23	25	31	24	36	29	36

Fetal outcome	Stillbirth	Neonatal death	Alive	Termination	Stillbirth	Stillbirth	Alive

	Masamoto et al. [5]	Lee et al. [6]	Matsuda et al. [7]

Warfarin dose (mg/day)	3.5	6–7	NA

Start of warfarin (weeks)	20	14	14

PT (INR)	2.7–2.9	2.2–3.0	NA

GA at diagnosis (weeks)	23	23	31

Hemorrhage site	Subdural	Subdural	Subdural

Delivery (weeks)	23	25	31

Fetal outcome	Stillbirth	Neonatal death	Alive

Oswal and Agarwal [8]	Ville et al. [11]	Ville et al. [11]	Present case

NA	3–6	5–6	3–4.5

24	26	15	12

NA	1.7–2.5	0.7–1.9	1.5–2.0

24	32	29	31

Subdural	Intraventricular	Intraventricular	Subdural

24	36	29	36

Termination	Stillbirth	Stillbirth	Alive


	Crude immediate brush material [21]	2-step ALI [5, 8, 22, 23]	2-step suspension [2, 3, 24, 25]	3D-E spheroids [9, 13]

Characteristics

 Sampling of cells	Nasal brush biopsy	Nasal brush biopsy	Removal of nasal polyp or nasal forceps biopsy	Removal of nasal polyp/nasal brush biopsy

 Anesthesia required	No	No	Yes	Yes (polyp removal)No (nasal brush)

 Preparation steps	Cell collectionCell dispersion	Cell collectionCell dispersionCell proliferation Ciliary regeneration	Tissue washingEnzymatic tissue digestionCell dispersionCell proliferationCiliary regeneration	Cell collectionCell dispersionSpheroid formation

 Longevity of cells/culture	1–3 days	>1 month	>1 month	At least 16 days

 Time from sampling to analysis	Immediately	4 weeks	4–6 weeks	24 h

 Materials and reagents	Falcon tubeNaClGlass slide	Falcon tubeCulture mediumT25/75 flask24-well plateTranswell insert filtersD-PBSTrypsin–EDTATrypsin-inhibitorCentrifugeCO2 incubator	Falcon tubePronaseCulture mediumPlastic plateCollagen gelCollagenaseT25/75 flaskGyrotori shakerCO2 incubator	Falcon tubeCulture medium24-well plateCO2 incubator

 Complexity	Simple	Complex	Complex	Simple

 Terminally differentiated cells	Yes	No	No	Yes

 Cell divisions	No	Yes	Yes	No

 Ciliogenesis	No	Yes	Yes	No

Known applications

 Diagnostics	Yes	Yes	Yes	Yes

 Study of transport mechanisms	No	Yes	No	Yes

 Study of ciliary physiology	Yes	Yes	Yes	Yes

Potential applications

 Study of drug effects	No	Yes	Yes	Yes

	Crude immediate brush material [21]

Characteristics

Sampling of cells	Nasal brush biopsy

Anesthesia required	No

Preparation steps	Cell collectionCell dispersion

Longevity of cells/culture	1–3 days

Time from sampling to analysis	Immediately

Materials and reagents	Falcon tubeNaClGlass slide

Complexity	Simple

Terminally differentiated cells	Yes

Cell divisions	No

Ciliogenesis	No

Known applications

Diagnostics	Yes

Study of transport mechanisms	No

Study of ciliary physiology	Yes

Potential applications

Study of drug effects	No

2-step ALI [5, 8, 22, 23]	2-step suspension [2, 3, 24, 25]	3D-E spheroids [9, 13]

Characteristics

Nasal brush biopsy	Removal of nasal polyp or nasal forceps biopsy	Removal of nasal polyp/nasal brush biopsy

No	Yes	Yes (polyp removal)No (nasal brush)

Cell collectionCell dispersionCell proliferation Ciliary regeneration	Tissue washingEnzymatic tissue digestionCell dispersionCell proliferationCiliary regeneration	Cell collectionCell dispersionSpheroid formation

>1 month	>1 month	At least 16 days

4 weeks	4–6 weeks	24 h

Falcon tubeCulture mediumT25/75 flask24-well plateTranswell insert filtersD-PBSTrypsin–EDTATrypsin-inhibitorCentrifugeCO2 incubator	Falcon tubePronaseCulture mediumPlastic plateCollagen gelCollagenaseT25/75 flaskGyrotori shakerCO2 incubator	Falcon tubeCulture medium24-well plateCO2 incubator

Complex	Complex	Simple

No	No	Yes

Yes	Yes	No

Yes	Yes	No

Known applications

Yes	Yes	Yes

Yes	No	Yes

Yes	Yes	Yes

Potential applications

Yes	Yes	Yes


Analysis	Description of measurement of benefits/effects	Hypothetical example applied to simulation

Cost minimisation analysis (CMA)	A comparison of costs when the effects are considered equal in all respects	Measurement of the simulation education method versus an alternative education method produced equivalent learning outcomes within a meaningful threshold; however, the simulation method is less costly.

Cost-effectiveness analysis (CEA)	Benefits/effects are measured in natural units (e.g. students educated)	Measurement of the simulation education method resulted in less clinical errors by the learner than the alternative education method.

Cost utility analysis (CUA)	Benefits/effects measured in ‘utility’ units—e.g. a measure of satisfaction derived from consumption/attainment of benefit	Measurement of the simulation education method resulted in higher levels of patient satisfaction with their care compared to the alternative education method.

Cost benefit analysis (CBA)	Benefits monetized	The simulation education method was measured to be of higher value (willingness to pay) by the learners when compared to the alternative education method.

Analysis	Description of measurement of benefits/effects	Hypothetical example applied to simulation

Cost-effectiveness analysis (CEA)	Benefits/effects are measured in natural units (e.g. students educated)	Measurement of the simulation education method resulted in less clinical errors by the learner than the alternative education method.

Cost utility analysis (CUA)	Benefits/effects measured in ‘utility’ units—e.g. a measure of satisfaction derived from consumption/attainment of benefit	Measurement of the simulation education method resulted in higher levels of patient satisfaction with their care compared to the alternative education method.

Cost benefit analysis (CBA)	Benefits monetized	The simulation education method was measured to be of higher value (willingness to pay) by the learners when compared to the alternative education method.


Variable	Solutions for the fixed effects using the mixed effect model	p-value

	Intercept	cos FA	cos2FA	cos3FA	Flexion/ extension	Natural/ TKA	Natural/ TKA


Preferred strategy	Patient characteristics

Invasive	Recurrent angina or ischaemia at rest or with low-level activities despite intensive medical therapy

	Elevated cardiac biomarkers (troponin I or T)

	New or presumably new ST-segment depression

	Signs or symptoms of heart failure or new or worsening mitral regurgitation

	High-risk findings from non-invasive testing

	Haemodynamic instability

	Sustained ventricular tachycardia

	PCI within 6 months

	Prior CABG

	High-risk score (e.g. TIMI, GRACE)

	Reduced left-ventricular function (LVEF < 40%)

Conservative	Low-risk score (e.g. TIMI, GRACE)

	Patient or physician preference in the absence of high-risk features

Preferred strategy	Patient characteristics

Conservative	Low-risk score (e.g. TIMI, GRACE)

	Patient or physician preference in the absence of high-risk features


			Nurses	Midwives

Baseline inputs	Doctors	Clinical officers	registered	enrolled	registered	enrolled	direct entry	Total

Number of staff

 At baseline (2008)1	806	1236	1453	5134	339	1711	0	10 679

 Minimum level required to meet need (same for all years)2	1778	3737	14 053	4751	24 319

Inflow from training

 Annual training enrolment (# of new students)3	74	155	660	423	136	173	174	1795

 Total years of training required3	7	3	3	2	1	1	2	n/a

 Graduation rate (% of students)3	90.0%	90.0%	96.7%	94.3%	97.1%	90.7%	90.0%	n/a

 Public sector entry rate from training schools (% of graduates)3,4	85.3%	91.4%	75.5%	81.4%	81.4%	81.4%	81.4%	n/a

 Inflow from immigration (# per year)4	20	0	0	0	0	0	0	20

Outflow from attrition

 Training program requires other professional diploma/degree and work experience before enrolling; or enrols students who leave the public sector workforce before enrolling	No	No	Yes	No	Yes	Yes	no	n/a

 If yes, which specific cadre is the feeder cadre for training programs	n/a	n/a	enrolled nurses	n/a	registered nurses	enrolled nurses	n/a	n/a

 Percent of enrolling students to which entry barrier applies (% per year)	n/a	n/a	14.89%	n/a	100%	100%	n/a	n/a

 Total attrition from cadre (% per year)	9.80%	4.48%	5.30%	4.48%	4.48%	4.48%	4.48%	n/a

 Involuntary attrition (% per year) [24,26]	6.66%	3.05%	3.60%	3.05%	3.05%	3.05%	3.05%	n/a

 Voluntary attrition (% per year) [25,26]	3.14%	1.43%	1.70%	1.43%	1.43%	1.43%	1.43%	n/a

			Nurses

Baseline inputs	Doctors	Clinical officers	registered	enrolled

Number of staff

At baseline (2008)1	806	1236	1453	5134

Minimum level required to meet need (same for all years)2	1778	3737	14 053

Inflow from training

Annual training enrolment (# of new students)3	74	155	660	423

Total years of training required3	7	3	3	2

Graduation rate (% of students)3	90.0%	90.0%	96.7%	94.3%

Public sector entry rate from training schools (% of graduates)3,4	85.3%	91.4%	75.5%	81.4%

Inflow from immigration (# per year)4	20	0	0	0

Outflow from attrition

Training program requires other professional diploma/degree and work experience before enrolling; or enrols students who leave the public sector workforce before enrolling	No	No	Yes	No

If yes, which specific cadre is the feeder cadre for training programs	n/a	n/a	enrolled nurses	n/a

Percent of enrolling students to which entry barrier applies (% per year)	n/a	n/a	14.89%	n/a

Total attrition from cadre (% per year)	9.80%	4.48%	5.30%	4.48%

Involuntary attrition (% per year) [24,26]	6.66%	3.05%	3.60%	3.05%

Voluntary attrition (% per year) [25,26]	3.14%	1.43%	1.70%	1.43%

Midwives

registered	enrolled	direct entry	Total

Number of staff

339	1711	0	10 679

4751	24 319

Inflow from training

136	173	174	1795

1	1	2	n/a

97.1%	90.7%	90.0%	n/a

81.4%	81.4%	81.4%	n/a

0	0	0	20

Outflow from attrition

Yes	Yes	no	n/a

registered nurses	enrolled nurses	n/a	n/a

100%	100%	n/a	n/a

4.48%	4.48%	4.48%	n/a

3.05%	3.05%	3.05%	n/a

1.43%	1.43%	1.43%	n/a


Neural-Network Parameters	Levenberg-Marquardt

Number of input parameters	3

Number of hidden neurons	9

Number of output parameters	1

Hidden transfer function	Sigmoidal

Output transfer function	linear

Maximum number of epochs	1000

Learning rate	0.01

Momentum rate	0.9

Stopping gradient	5.5292 × 10−8

MU (momentum )	1 × 10−8


	Intervention	Control

(n, first year)	(n = 343)	(n = 350)

(n, second year)	(n = 330)	(n = 241)	P (2)

(n, both years)	(n = 673)	(n = 591)

Received the study leaflet

 First year	37.0	20.0	0.005

 Second year	48.2	44.4	0.748

 Both years	42.5	29.9	0.090

Seen the study poster

 First year	27.7	12.6	0.016

 Second year	50.6	34.4	0.142

 Both years	38.9	21.5	0.014

Received the advice on maternal care from township midwives

 First year	70.0	49.1	0.031

 Second year	63.9	64.7	0.942

 Both years	67.0	55.5	0.196

Received the advices on maternal care from FP worker

 First year	16.0	17.4	0.797

 Second year	33.3	37.8	0.698

 Both years	24.5	25.7	0.858


Intake	All dysphagic patients (N = 120)	Spinal onset dysphagic patients (N = 64)	Bulbar onset dysphagic patients (N = 56)	p

Normal	8 (7)	7 (11)	1 (2)	ns

Postural	31 (26)	20 (31)	11 (20)	ns

Syrup/nectar	13 (11)	12 (19)	1(2)	0.007

Cream	43 (36)	22 (34)	21 (37)	ns

Percutaneous endoscopic gastrostomy	25 (20)	3 (5)	22 (39)	0.0001

Intake	All dysphagic patients (N = 120)	Spinal onset dysphagic patients (N = 64)	Bulbar onset dysphagic patients (N = 56)	p

Percutaneous endoscopic gastrostomy	25 (20)	3 (5)	22 (39)	0.0001


 Frequency (%) questions	Most often	sometimes	Not often	never	No answer

How often are you giving oral health education to school (nurseries) children?	48 (19.7)	70 (44.6)	19 (12.1)	20 (12.7)	—

How do you supervise fluoride mouth wash programme in school?	31 (19.7)	54 (34.4)	20 (12.7)	52 (33.2)	10 (6)

Are you examining mouth and teeth of pregnant women?	59 (37.6)	35 (22.3)	17 (10.8)	46 (29.3)	—

How do you refer the patients to dentist or oral hygienist?	76 (48.4)	37 (23.6)	19 (12.1)	25 (15.9)	—

	yes	no	No answer

Have you had any partnership with parents regarding oral health?	45 (28.7)	112 (71.3)	—

Have you had any partnership with other health sector regarding oral health?	24 (15.3)	133 (84.7)	—

Do you know about the water fluoride content of your area?	26 (16.6)	107 (68.1)	24 (15.3)

Do you have any information about oral health status (DMFT/CPITN) of the population under your care?	55 (35)	102 (65)	—

Do you complete the annual oral health report form?	76 (30.2)	81 (51.6)	—

Frequency (%) questions	Most often	sometimes	Not often	never	No answer

How often are you giving oral health education to school (nurseries) children?	48 (19.7)	70 (44.6)	19 (12.1)	20 (12.7)	—

How do you supervise fluoride mouth wash programme in school?	31 (19.7)	54 (34.4)	20 (12.7)	52 (33.2)	10 (6)

Are you examining mouth and teeth of pregnant women?	59 (37.6)	35 (22.3)	17 (10.8)	46 (29.3)	—

How do you refer the patients to dentist or oral hygienist?	76 (48.4)	37 (23.6)	19 (12.1)	25 (15.9)	—

	yes	no	No answer

Have you had any partnership with parents regarding oral health?	45 (28.7)	112 (71.3)	—

Have you had any partnership with other health sector regarding oral h	24 (15.3	133 (84.

Frequency (%) questions	Most often	sometimes	Not often

ealth?	)	7)	—

Do you know about the water fluoride content of your area?	26 (16.6)	107 (68.1)	24 (15.3)

Do you have any information about oral health status (DMFT/CPITN) of the population under your care?	55 (35)	102 (65)	—

Do you complete the annual oral health report form?	76 (30.2)	81 (51.6)	—


Type of study	Scale of analysis	Data sources	Interviewee profiles	No. of interviewees

History of free care	National	Scientific literature, administrative archives and print media, in-depth semi-structured interviews	Health, agriculture and education (decision-makers, technicians, implementers)	n = 28

Fee exemptions for malaria (prevention, treatment)	District (Hauts-Bassins region)	Scientific literature, routine data, in-depth semi-structured interviews, group discussions	Decision-makers, local actors (NGOs, associations) and healthcare providers	n = 63

Antiretroviral drug exemptions for children and adults	Regional (Centre and Hauts-Bassins regions)	Scientific literature, routine data, semi-structured interviews	Institutional decision-makers, local actors (NGOs, associations), healthcare providers, service users	n = 30

Type of study	Scale of analysis	Data sources	Interviewee profiles	No. of interviewees

	Nati	Scientific literature, administrative archives	Health, agriculture and education 	n =

Type of study	Scale of analysis	Data sources	Interviewee profiles	No. of interviewees

History of free care	onal	 and print media, in-depth semi-structured interviews	(decision-makers, technicians, implementers)	 28

Fee exemptions for malaria (prevention, treatment)	District (Hauts-Bassins region)	Scientific literature, routine data, in-depth semi-structured interviews, group discussions	Decision-makers, local actors (NGOs, associations) and healthcare providers	n = 63

Antiretroviral drug exemptions for children and adults	Regional (Centre and Hauts-Bassins regions)	Scientific literature, routine data, semi-structured interviews	Institutional decision-makers, local actors (NGOs, associations), healthcare providers, service users	n = 30


	Raw data		Clean data

Number of reads	300,582		23,498

Number of nucleotides (bp)	673,594,247		20,685,462

Longest read length (bp)	11,914		2,261

Mean read length (bp)	2,241		880

Genome coverage %		100%

Average depth of coverage		132×

Number of contigs		1

Whole cp genome length (bp)		156,749

Run time		45 min×2

Total DNA requirements (ng)		700


Apicomplexan species 	Positive training set 	Negative training set

B. bovis 	18 	30

B. microti 	23 	22

C. hominis 	1 	28

C. muris 	0 	34

C. parvum 	2 	33

E. tenella 	30 	143

N. caninum 	21 	77

P. berghei 	49 	94

P. chabaudi 	51 	98

P. cynomolgi 	31 	90

P. falciparum 	51 	132

P. knowlesi 	48 	90

P. vivax 	51 	101

P. yoelii 	41 	87

T. annulata 	23 	41

T. parva 	25	61

T. gondii 	 42 	86


Variables	N	Pre-intervention	Post intervention	p-value

TUG (sec)	37	9.35 (7.16;12.62)	8.34 (6.27;11.12)	<0.01


Compound	Spiked concentration (μg/mL)	Intraday	Interday

Detected concentration (μg/mL)	RSDa (%)	Detected concentration (μg/mL)	RSD (%)

Gallic acid	5	5.03	2.57	5.30	1.77

10	9.64	1.80	9.59	2.02

20	20.17	0.42	20.13	0.58

Ellagic acid	5	5.34	0.78	5.45	2.80

10	9.67	2.14	9.88	2.26

15	15.11	0.95	14.93	1.27

Compound	Spiked concentration (μg/mL)	Intraday	Interday

Detected concentration (μg/mL)	RSDa (%)	Detected concentration (μg/mL)	RSD (%)

Eugenol	10	10.52	0.83	10.39	0.36

25	25.09	0.28	25.16	0.14

40	39.81	0.12	39.81	0.08


	Naïve	GBT

	Train Acc	Test Acc	Train Acc	Test Acc